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 i 
Abstract 
 
Breast and prostate cancer are the most frequently diagnosed cancers in women and men 
respetively, in North America. Triple-negative breast cancer (TNBC) cells do not express 
estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 (HER-
2). TNBC accounts for 15% of all breast cancer cases, is aggressive in nature, and is 
characterized by resistance to chemo and radiotherapy thus, finding new approaches to inhibit it 
are urgently needed. Similarly, prostate cancer is typically characterized by the expression of 
androgen receptor (AR) and prostate-specific antigen (PSA). Prostate cancer that is AR positive 
can be treated with hormonal therapy. In contrast, AR negative prostate cancer is more 
aggressive and does not respond to hormone therapy, thus new approaches, including identifying 
specific signaling molecules that are overactivated and could be targeted, are required to 
effectively treat this subtype of prostate cancer. 
Rosemary extract (RE) has been shown to have anti-cancer properties in vitro and in vivo. 
However, limited evidence exists regarding its effect on triple-negative breast cancer and AR 
negative prostate cancer. In this study, we examined the effects of RE on triple-negative breast 
cancer cell (MDA-MB-231) and androgen insensitive prostate cancer cell (PC-3) proliferation, 
survival/apoptosis, and migration. In addition, we investigated the effect of RE treatment on key 
signaling molecules involved in cancer cell proliferation and survival.  
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Chapter 1: Literature Review 
1.1 Cancer 
Cancer is currently the leading cause of death in developed countries, accounting for an 
estimated 18.1 million new cases and 9.6 million deaths worldwide in 2018 [1]. The adoption of 
negative lifestyle behaviours such as smoking, physical inactivity, poor diet, and nutrient 
overload, have all further increased the global burden of cancer [2].  
Cancer is driven by genetic and epigenetic modifications that lead to increased survival and 
proliferation of cancer cells, while evading apoptosis [3]. This increase in cell proliferation and 
survival is caused by modulation of signaling pathways that regulate these processes [3]. 
Mutations that convert proto-oncogenes to oncogenes cause an overactivation of signaling 
pathways resulting in enhanced proliferation and survival, together with the inhibition/down 
regulation of tumor suppressor proteins leads to carcinogenesis [3]. Most cancers are epithelial in 
origin, manifesting as carcinomas in organs such as the lungs, skin, breast, liver, prostate, and 
pancreas [3]. Sarcomas are mesenchymal in origin, occurring in fibroblasts, myocytes, 
adipocytes, and osteoblasts [3]. Other types of cancers which are not epithelial in origin can 
develop in the nervous system or hematopoietic tissue.  
Cancer cells acquire key changes in their biological capabilities leading to the development 
of human tumors [4]. These capabilities enable growth and metastatic potential of cancer cells 
[4]. The ten recognized hallmark capabilities of cancer are sustaining proliferative signaling, 
evading growth suppressors, activating invasion/metastasis, enabling replicative immortality, 
inducing angiogenesis, tumor-promoting inflammation, avoiding the immune system, 
deregulating cellular energetics, genome instability/mutation and resisting cell death (Figure 1) 
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[4]. Possibly the most fundamental trait of cancer cells is their ability to sustain their hyper-
proliferative capability [4]. Normal cells control the production and release of growth-promoting 
signals, thereby maintaining homeostasis. Cancer cells deregulate these signals by increasing 
growth factor production and/or growth factor signaling. Growth factor receptors are cell-surface 
receptors that contain intracellular tyrosine kinase domains [3–5]. These receptors proceed to 
increase the activation of signaling pathways that regulate cell growth. The mechanisms by 
which cancer cells acquire the ability to sustain proliferation can occur by the cell producing 
growth factor ligands themselves, leading to autocrine proliferative stimulation [4]. In normal 
cells, cell-to-cell contact as a result of dense cell populations will suppress further proliferation, 
whereas this feature of contact inhibition is abolished in cancer cells [4]. Cancer cells can also 
sustain proliferation by increasing the levels of receptor proteins displayed on the cell’s surface, 
which will cause the cell to become hyper-responsive to growth factor ligands [4]. These are the 
most commonly mutated/hyperactive receptors. 
In order to maintain their proliferative capabilities cancer cells will also evade signals from 
genes that inhibit growth-stimulation. These tumor suppressor genes operate to limit cell growth 
and activate senescence. Cancer cells will evade apoptosis, which is a programmed cell death 
that serves as a barrier to cancer development [4]. Apoptosis is controlled by two major 
pathways; one of which is responsible for receiving and processing extracellular death-receptor 
signaling (extrinsic pathway) and the other which is responsible for sensing intracellular signals 
(intrinsic pathway) [4]. Both pathways activate effector caspases that result in cellular 
disassembly [4]. The extrinsic pathway is triggered by the binding of Fas plasma-membrane 
death receptors with its extracellular ligand Fas-L [4,6]. When bound, a death complex is formed 
and recruits Fas associated death domain-containing protein (FADD) and pro-caspase 8 [6]. This 
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leads to pro-caspase 3 activation, which is the main enzyme responsible for apoptosis. The 
intrinsic pathway, also known as the mitochondrial pathway, will cause outer mitochondrial 
membranes to become permeable to cytochrome c in the presence of intracellular signals [4,6,7]. 
Cytochrome c is released in the cytosol and recruits pro-caspase 9, which activates downstream 
pro-caspase 3 and leads to apoptosis [4,6,7]. The balance between pro- and anti-apoptotic 
members of the Bcl-2 family of proteins plays a role in overall apoptosis/survival [4]. The Bcl-2 
family is comprised of pro-apoptotic members such as Bax, Bak, and Bad, and anti-apoptotic 
members such as Bcl-2, Bcl-w and Bcl-XL [4,6,7]. Following a death signal, pro-apoptotic 
proteins undergo a post-translational modification that leads to their activation and translocation 
from the mitochondria, which allows apoptosis to occur [6]. Another key hallmark of cancer 
cells is their ability to induce angiogenesis. Angiogenesis is the sprouting of new blood vessels, 
which allows cancer cells to sustain nutrients and oxygen availability [4]. Vascular endothelial 
growth factor-A (VEGF-A) is a angiogenesis inducer that is involved in the development of new 
blood vessels during embryonic and postnatal development and induces its effects in target 
cells/tissues by activating three tyrosine kinase receptors (VEGFR-1-3) [4].    
Cancer cells are characterized by their ability to proliferate uncontrollably and evade 
apoptosis [4,8]. These characteristics are often acquired as a result of mutations in key proteins 
involved in the signaling pathways responsible for regulating celluar function and maintaining 
homeostasis [5,9–15]. Molecular signaling pathways of growth factor receptors; such as 
Epidermal Growth Factor (EGF) Receptor (EGFR) initiate signal transduction pathways such as 
the phosphatidylinositol 3-kinase (PI3K)/Akt and the Ras/mitogen-activated protein kinase 
(MAPK) pathway, which can lead to increase cell proliferation and survival [5,9,10,13,16–20]. 
Oncogenic mutations cause affected genes to be amplified and/or produce mutated proteins with 
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dysregulated activity [3]. Some of the commonly mutated proteins are growth factor receptor 
tyrosine kinases (RTKs-such as epidermal growth factor receptors, EGFR), GTPases (Ras), 
serine/threonine kinases (Raf and Akt), lipid kinases (phosphoinositide 3-kinases, PI3Ks), 
cytoplasmic tyrosine kinases (Src) and nuclear receptors (estrogen receptor, ER) [3]. Other 
mutations result in inactivation of proteins that serve as tumor suppressors. The most commonly 
mutated gene in cancer is the tumor suppressor gene p53 [3,21]. p53 controls cell proliferation 
and stress signals such as apoptosis and DNA damage responses and its loss/down regulation 
results in enhanced proliferation and inhibition/suppression of apoptosis [3].  
Cancer cells are characterized by their ability to alter their metabolic capabilities to maintain 
long-term growth, proliferation, and survival, by altering key signaling pathways involved in 
metabolism and survival processes [3,22,23]. This altered metabolism allows for the increased 
uptake of glucose and the production of lactate [22]. Both normal and cancer cells obtain their 
energy from glucose however the processes employed to generate adenosine triphosphate (ATP) 
markedly differ between these phenotypes. Normal cells undergo aerobic respiration involving 
cytoplasmic glycolysis and mitochondrial oxidative phosphorylation in conditions with oxygen 
availability while reverting to glycolysis in low-oxygen states [24,25]. However, cancer cells 
preferably metabolize glucose through glycolysis and produce lactate regardless of oxygen levels 
[24,25]. This phenomenon, known as the Warburg Effect, was first observed by Otto Warburg in 
the 1920s [22]. In tumors and proliferating cells, the rate of glucose uptake and the production of 
lactate increases, even with a sufficient oxygen supply and fully functioning mitochondria [22]. 
Lactate secretion increases the acidity of the tumor microenvironment, which can drive cell 
proliferation and modulate tumor progression [22,26]. The rate of glycolysis and glucose uptake 
are increased in cancer cells to maintain the increased need for energy production and 
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compensate for the inefficient energy producing pathway [27,28]. The process of glucose uptake 
is thereby crucial in driving forward the process of glycolysis and maintaining an adequate 
supply of energy to the cell [29]. Therefore, the increased cancer cell demand for glucose is 
compensated by an increased rate of uptake into cell. The ATP yield from glycolysis is much 
lower than the amount obtained through mitochondrial oxidation however, glycolysis occurs at a 
10-100-time faster rate [22].  
 
 
Figure 1. Acquired capabilities of cancer cells. 
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1.2 Breast Cancer  
Breast cancer is the most frequently diagnosed cancer in women, accounting for roughly 
2.1 million newly diagnosed cases and 626,700 deaths worldwide in 2018 [1]. Of these 
diagnosed cases, it is estimated that over 15% will display the triple-negative phenotype [30,31]. 
Most triple negative (TN) breast cancers (TNBCs) will be basal-like in gene expression, which 
exhibits a unique profile and characteristics. TN breast cancer is aggressive, shows an early 
pattern of metastasis, does not respond to hormone therapy, and as a result limited treatment 
options are available [10,30]. Additionally, TN breast cancer tends to relapse more frequently 
and have the worst prognosis of all breast cancer subtypes, this is attributable to the aggressive 
nature of the disease and the lack of reconigzed molecular targets for therapy [32]. Studies have 
shown that patients withTNBCs have a much higher death rate than patients with any other 
breast cancer subtype [33], alongside an incidence rate that is two to three times higher in 
African-American women [31,34].  
In a clinical setting breast cancer is divided into subtypes based on mutations/cancer 
biology, this classification serves both prognostic and therapeutic significance. Typically, breast 
cancer will exhibit the expression of estrogen receptor (ER), progesterone receptor (PR) and an 
amplification of HER-2, as determined by immunohistochemistry (IHC) [35,36]. These markers 
allow for breast cancer tumors to be classified as hormone receptor positive, HER-2 
amplification tumors, or as TNBCs, which do not express ER, PR, and do not have HER-2 
amplification [35]. Tumors that express hormone receptors are generally treated with agents that 
interfere with hormone production or inhibit ER signaling [35,37]. These tumors tend to have a 
more favourable outcome, when compared to tumors with HER-2 amplification or TNBCs [35]. 
Tumors that express HER-2 amplification are treated with agents that are tyrosine kinase 
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inhibitors, such as trastuzumab-based therapy [35,36].  
In estrogen receptor positive breast cancer, the binding of the hormone to its receptor leads 
to downstream activation of the Ras/MAPK and PI3K/Akt pathways [9,37–39] and therefore 
estrogen receptor signaling has a huge impact on the progression of this subset of breast cancer. 
Similarly, studies have found that dysregulation of the human epidermal growth factor-2 receptor 
in breast cancer cells promotes the sequestration of estrogen receptor, leads to downstream 
activation of the Ras/MAPK cascades and enhances proliferation [37–39]. Despite the absence of 
these receptors in TNBCs the signaling pathways that regulate cell survival and proliferation 
remain in an overactivated state. Due to the fact that TN breast cancers do not express these 
receptors there are no targeted therapies specifically for this sub-class of breast cancer [30]. 
Studies have shown that while triple negative breast cancers may respond well to primary 
chemotherapeutic agents such as taxane-based therapies, there is a high risk of relapse if the 
tumor is not eradicated [30]. 
The current treatment strategies for breast cancer are surgery, radiotherapy, and 
chemotherapy. Radiotherapy is often given to TNBC patients following a mastectomy or 
conservative breast surgery [36]. Specific adjuvant treatments are not very effective in TNBC so 
polychemotherapeutic agents, such as those offered to high-risk patients are often used and are 
most effective [36]. The most frequently used first-line treatment for TNBCs are taxane-based 
therapies [40] and currently therapies targeting apoptotic proteins, EGFR, fibroblast growth 
factor receptor-2 (FGFR-2), vascular endothelial growth factor (VEGF), and mTOR (mechanistic 
target of rapamycin), are being developed [36]. Also, the identification of molecular biomarkers 
in TNBCs is crucial in improving treatment strategies and patient prognosis, since this type of 
cancer is highly aggressive and difficult to treat due to a lack of targeted therapies [36].   
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1.3 Prostate Cancer 
 Prostate cancer accounted for 1.3 million new cases and roughly 359,000 deaths in 2018 
globally [1]. It is the most frequently diagnosed cancer in 105 countries, including Canada, the 
United States and Australia [1,2]. It has been noted that mortality from prostate cancer has 
increased over the course of the past two decades and is the leading cause of death among men in 
46 countries particularily in Sub-Saharan Africa and the Carribean [1,2].  
Prostate cancer occurs when the cellular homeostasis of the prostate is disrupted [41]. 
Androgens are an important growth factor for normal prostate cells, and androgen receptor (AR) 
is typically expressed in the stromal and epithelial compartments of these cells [41,42]. AR is a 
member of the steroid hormone receptor family. The growth of prostate cells are dependent on 
the expression and function of this receptor [41,43]. Production of luteinizing hormone (LH)- 
releasing hormone (LHRH) by the hypothalamus induces the production of LH by the pituitary 
[44]. Hypothalamic LHRH production is inhibited when ligands bind to ER, PR, or AR receptors 
[44]. Androgenic activation of the AR leads to transcriptional activity of AR target genes which 
are involved in various biological processes such as proliferation and apoptosis [41,43]. When 
activated by androgenic ligands, testosterone (T) and dihydrotestosterone (DHT), androgen 
receptors cause the dimerization and translocation of the ligand-receptor complex to the nucleus 
and act as a transcription factor for induction of different genes [42,43]. Alternatively, the AR 
complex can lead to the activation of the PI3K/Akt and MAPK pathways [42]. Therefore, AR 
signaling is directly involved in maintining the balance between proliferation and 
survival/apoptosis of prostate cells [41]. Aberrant AR expression, activation of oncogenes, and 
the impairment of tumor suppressor genes, specifically p53, p27, and phosphatase and tensin 
homologue (PTEN), contribute to the development of prostatic tumors [45–47]. 
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Prostate-specific antigen (PSA) is a serine protease, is synthesized in healthy prostate 
tissue, benign tumors, and prostate cancer tumors of all grades/stages [48]. PSA concentrations 
range from roughly 0.3-3 mg/mL [49]. In prostate cancer it is released in the circulatory system 
and increases blood PSA levels up to a 100,000 fold can be seen [48]. PSA testing has become a 
marker for initial prostate cancer diagnosis and monitoring treatment response [48]. Men with 
metastatic prostate cancer will have higher PSA levels compared to localized prostate cancer and 
patients with higher PSA levels at the time of initial diagnosis have an increased risk of 
reoccurrence [48]. However, recent evidence has shown that in high-grade prostate cancer, PSA 
levels <4 ng/mL have been reported [48,50] and up to 10% of prostate tumors produce very trace 
amounts of PSA [50]. Thus, low PSA levels in high grade prostate cancer (fast growing and 
likely to spread) may be indicative of differentiation and a poor prognosis [50].  
 The current treatment strategies for prostate cancer include surgery, radiotherapy, and 
chemotherapy [51]. Patients with localized prostate cancer are most often treated with radical 
prostatectomy or radical radiotherapy, however advanced and metastatic prostate cancer is 
treated with hormonal therapy [51]. Common hormonal therapies often use androgen-receptor 
inhibitors or LHRH agonists (such as leuprolide, goserelin, buserelin, or nafarelin) that initially 
increase testosterone production, but with prolonged exposure downregulate the LHRH receptor 
and inhibit testosterone production [44]. LHRH antagonists (such as cetrorelix, abarelix, or 
orgalutran) directly inhibit LHRH, which decreases testosterone production [44]. Surgical 
castration can also decrease T levels by removing the source of production. Many patients do not 
respond to androgen therapies and therefore, cytotoxic chemotherapeutic agents, such as 
etoposide, doxorubicin, paclitaxel, and docetaxel as are used as combination therapies for 
prostate cancer [44]. 
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1.4 Cancer Cell Enhanced Proliferation 
 Cancer is a complex and multifactorial disease that often involves the over-expression of 
receptors, growth factors, oncogene activations, and the inactivation of tumor suppressor genes 
[52]. Epidermal growth factor receptors (EGFRs) are frequently mutated/over-expressed in 
cancer. The EGFR belongs to the ErbB family of tyrosine kinase receptors (RTK) [23]. Their 
physiological role is to regulate epithelial tissue development and maintain homeostasis [53]. 
However, primarily in breast and lung cancer EGFR is a driver of tumorigenesis [53]. The ErbB 
family of RTKs is composed of four receptors; the EGFR (also known as ErbB-1/HER-1), ErbB-
2 (neu, HER-2), ErbB-3 (HER-3), and ErbB-4 (HER-2) [23,52]. These transmembrane 
glycoproteins have molecular weights ranging from 170-185 kDa [52].  
All proteins in this family contain an extracellular ligand-binding domain, a hydrophobic 
transmembrane domain, and cytoplasmic tyrosine kinase-containing domain [23,52]. ErbB 
receptors can be activated by binding to ligands of the EGF-family that are produced by cells that 
express these receptors (autocrine signaling) or by surrounding cells (paracrine signaling) [23]. 
EGFRs are activated by the binding of a ligand to the extracellular domain of these receptors and 
induce the formation of heterodimers, which activate the kinase domain, thereby triggering the 
signaling cascade [23,53]. Receptor activation will lead to the auto-phosphorylation of tyrosine 
residues within the cytoplasmic tail [23]. These residues then serve as docking sites for proteins 
containing Src homology 2 (SH2) and phosphotyrosine binding (PTB) domains of intracellular 
effector proteins [23,52]. These effector proteins will lead to the activation of signaling cascades 
such as the Ras/MAPK pathway, PI3K/Akt pathway, the anti-apoptotic Akt pathway, and the 
JAK/STAT signaling pathway, which are involved in cell proliferation, angiogenesis, migration, 
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survival, and adhesion [52]. In malignant cells these pathways are often dysregulated due to the 
occurance of mutations in various genes involved in these pathways [52,54]. 
 
1.5 PI3K-Akt/PKB  
 Overactivation of the phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B) 
pathway plays a key role in tumorigenesis [55,56]. PI3K is a lipid kinase that causes 
phosphorylation of membrane phospholipids on the 3-position resulting in the generation of 
phosphatidylinositol-3,4,5-triphosphate (PIP3), which contributes to activation of downstream 
targets such as the serine-threonine protein kinase Akt [57]. PI3K is a heterodimer consisting of a 
p85 regulatory subunit and p110 catalytic subunit [57,58]. In response to RTK activation, PI3K 
is recruited to the membrane through the interaction of the Src-homology 2 (SH2) domain of the 
p85 subunit to tyrosine phosphorylated residues of the activated receptor or to proteins 
associated with the receptor [57,58]. Ras, a GTPase can also activate PI3K by binding directly to 
the p110 subunit [57]. At the membrane PI3K will convert phosphatidylinositol-4,5-bisphosphate 
(PIP2) to phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 will then recruit other 
downstream molecules by binding to their pleckstrin-homology (PH) domains [57]. PIP3 levels 
are highly regulated and the lipid phosphatase PTEN acts to rapidly remove it by converting 
PIP3 back to PIP2, thereby suppressing the PI3K pathway [57]. PTEN is a major tumor 
suppressor gene and a loss of function mutation of PTEN is highly common in both breast and 
prostate cancers [57]. Gene amplification of the p110 subunit occurs in ovarian cancer and 
amplification of Akt is found in ovarian, breast, and colon cancer [57]. Studies analyzing human 
tumors have shown that at least 33% of TN breast cancers have dysregulated PI3K/Akt pathways 
and 11.3-35% have a mutation/loss-of-function of the PTEN gene [59,60]. Inactivation of PTEN 
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by mutation or deletion is identified in roughly 20% of primary prostate tumors and in as many 
as 50% of castration-resistant tumors [61]. Additionally, Akt over-expression is associated with 
increased resistance to chemotherapeutic agents such as cisplatin, methotrexate, or paclitaxel 
[62,63]. Due to the importance of these signaling proteins, several small molecules that 
target/inhibit Akt are currently in clinical development [64–67].  
 
1.5.1 mTOR 
 The 289 kDa serine/threonine kinase mechanistic target of rapamycin (mTOR), is a 
downstream effector of the PI3K/Akt pathway, found in two complexes: mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2) [68]. mTORC1 is sensitive to rapamycin, is 
involved in mRNA translation and is activated by signaling pathways such as PI3K, MAPK, and 
5’ adenosine monophosphate-activated kinase (AMPK), in order to control cell growth and survival 
[68]. mTORC1contains a regulatory associated protein known as RAPTOR, which regulates its 
activity and recruits mTORC1 substrates [68–71].  mTORC2 is not sensitive to rapamycin or 
energy signals, but rather regulates the actin cytoskeleton [68,72]. mTORC2 contains Rictor, 
which is a rapamycin-insensitive companion of mTOR [71,73]. The serine/threonine kinase 
mTOR is highly involved in the control of cell growth in mammalian cells, the PI3K pathway 
activates mTOR to stimulate cell growth [74]. Several tumor suppressors such as tuberous 
sclerosis complex 1 (TSC1 or hamartin), tuberous sclerosis complex 2 (TSC2 or tuberin), and 
serine/threonine protein kinase 11/liver kinase B1 (LKB1)  can inhibit mTOR signaling [74]. 
Thus, the inactivation of TSC1, TSC2, LKB1, and PTEN play a key role in the development of 
cancer. The serine/threonine kinase p70S6K is a well-known downstream target of mTORC1. 
Activated mTORC1 phosphorylates p70S6K, which phosphorylates S6 and leads to mRNA 
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translation [68]. Many upstream elements can lead to alterations in mTOR expression and can 
have major effects on tumor progression. As a result mTOR is an appealing target for 
chemotherapeutic agents and mTOR inhibitors such as sirolimus, deforolimus, everolimus, and 
temsirolimus are used as a monotherapy or combined therapy for various types of cancers 
[62,68,75]. 
 
1.6 Ras-MAPK  
 Ras is a human oncogene that was first reported in cancer over three decades ago, it 
regulates physiological processes such as cell proliferation and survival [76]. Ras GTPase cycles 
between the active state when bound to guanosine triphosphate (GTP) by guanine nucleotide 
exchange factors (GEFs) and the inactive state when bound to guanosine diphosphate (GDP) by 
GTPase-activating proteins (GAPs) that catalyze GTP hydrolysis [15]. When in the active state, 
GTP bound Ras can activate downstream effectors such as the PI3K and the mitogen-activated 
protein kinase (MAPK) pathways [15].  
 Receptor tyrosine kinase (RTK) activation by ligand binding leads to dimerization and 
autophosphorylation of tyrosine sites in their cytoplasmic domains [19,77]. The phosphorylated 
tyrosine residues create binding sites for the Src homology 2 (SH2) domain on growth factor 
receptor binding protein 2 (Grb2) [77]. Grb2 is associated with SOS (sons-of-sevenless), a set of 
genes encoding GEFs, that exchange GDP for GTP to increase Ras-GTP levels [77]. Activated 
Ras will then signal its downstream effectors such as the Raf-1 serine/threonine kinase [77]. Raf 
will then activate two MAPK kinases (MEK1 and MEK2), which will phosphorylate 
extracellular signal regulated kinases (ERKs) [77]. Activated MAPKs translocate to the nucleus 
and activate various substrates that regulate protein synthesis.  
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Mutated Ras is a driver of tumor initiation [15]. There are three human Ras genes (K-Ras, 
N-Ras, and H-Ras) that encode 4 Ras proteins [15,78]. Overactivation of Ras can occur in tumors 
without a Ras mutatation by the loss of function of the tumor suppressor neurofibromin 1 (NF1), 
which encodes a GAP for Ras [15]. Loss of function of this tumor suppressor specifically results 
in an accumulation of activated GTP bound Ras and decreased GTP hydrolysis [15]. 
Mitogen-activated protein kinase (MAPK) pathways control cell growth, proliferation, 
differentiation, migration, and apoptosis [14]. They are comprised of three-tier kinases where by 
a MAPK is activated upon phosphorylation of a mitogen-activated protein kinase kinase 
(MAPKK), which is activated upon phosphorylation of a MAPKKK [14].  
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Figure 2. Cell proliferation and survival pathways. The PI3K/Akt and Ras/MAPK pathways 
play a significant role in cancer and are involved in regulating cell proliferation, survival, 
apoptosis, and migration. 
 
1.7 Cancer Cell Evasion of Apoptosis  
Apoptosis is controlled by two pathways, an extrinsic pathway, responsible for receiving 
and processing extracellular death-receptor signaling and an intrinsic pathway, responsible for 
sensing intracellular signals [4]. Both pathways will activate effector caspases that promote 
cellular disassembly, and are made up of upstream regulator and downstream effector molecules 
[4]. Caspases are cysteinyl-aspartate proteases, that are initially synthesized as pro-caspases and 
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cleaved upon activation. The extrinsic pathway involves plasma-membrane bound death 
receptors with its extracellular ligand Fas-L [4,6]. When bound, a death complex is formed and 
will recruit Fas associated death domain-containing protein (FADD) and caspase 8 [6]. Caspase 
8 will then activate the downstream effector caspase 3, which is the main enzyme responsible for 
apoptosis. The intrinsic pathway does not involve receptors, but instead will cause outer 
mitochondrial membranes to become permeable to cytochrome c in the presence of intracellular 
signals [4,6,7]. Cytochrome c is released in the cytosol and will recruit pro-caspase 9, which 
activates downstream caspase 3 to execute apoptosis [4,6,7]. The trigger that controls apoptotic 
signaling is the balance between pro- and anti-apoptotic members of the Bcl-2 family of proteins 
[4]. The Bcl-2 family is comprised of pro-apoptotic members such as Bax, Bak, and Bad, and 
anti-apoptotic members such as Bcl-2, Bcl-w and Bcl-XL [4,6,7]. Following a death signal, pro-
apoptotic proteins undergo a post-translational modification that leads to their activation and 
translocation from the mitochondria so that apoptosis can occur [6]. 
The poly ADP-ribose polymerase (PARP) family of proteins play a key role in cell 
apoptosis. PARP is a known substrate of caspases, and it has been shown that caspase 3 and 
caspase 7 can cleave PARP [79]. PARP is cleaved into fragments by caspase 3/7 which 
inactivates the enzyme by destroying its ability to respond to DNA strand breaks [80]. The 
cleavage of PARP by caspases results in the formation of an 89 kDa catalytic fragment and a 24 
kDa fragment. PARP helps cells maintain their viability while cleaved PARP is a known 
indicator of cell apoptosis, as it promotes cellular disassembly [81–83]. 
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Figure 3. Intrinsic and extrinsic caspase cell signaling pathways. These pathways are involved 
in regulating apoptosis and represent the different mechanisms of programmed cell death from 
p53 activation.  
 
1.8 Cancer Cell Enhanced Migration  
 Matrix metalloproteinases (MMPs) belong to a family of zinc- and calcium-dependent 
metalloproteinases that are responsible for remodeling the extracellular matrix (ECM) [84,85]. 
These MMPs are necessary for wound repair and cell growth/development [84]. MMP mRNA 
expression is  typically at low levels, however these levels increase with inflammation, wound 
healing or in cancer [86]. Enzymes that degrade the ECM are essential for tumor progression, 
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and can promote cancer cell invasion onto surrounding tissues, entry into blood vessels, and 
allows cancer cells to metastasize to distant organs [86]. MMP-9 (92 kDa) specifically, plays a 
key role in these physiological processes and as a result elevated levels of MMP-9 is associated 
with increased metastatic capabilities in many types of cancer cells, including breast and prostate 
cancer cells [85].  
 Different types of cell adhesion are regulated by various adhesion molecules, for example 
cell to cell adhesions are formed by the E-cadherin complex [87]. For cell invasion to occur 
single cells must separate from the tumor, this requires a loss of cell-to-cell adhesion and a gain 
of cell-matrix adhesion properties [87]. The PI3K/Akt and Ras/MAPK pathways can modulate 
cell migration by increasing downstream MMP-9 production and thus playing a role in the 
progression of cancer [87].  
 
1.9 Natural Compounds in Cancer Therapy 
Over 50% of modern chemotherapeutic agents that are used for cancer treatment have 
been derived from natural products, either directly from plants or other sources [88,89]. For 
example the chemotherapeutic treatments paclitaxel and docetaxel, were originally isolated from 
the bark of the Pacific yew (Taxus brevifolia) plant [90]. Many labs, including ours have shown 
metformin [91,92], a drug derived from the plant Galega officinalis, commonly known as French 
lilac, has anticancer properties. Plant derived extracts with high polyphenolic content such as 
green tea [93], rosemary extract [94,95], as well as individual polyphenols such as quercetin 
[96], resveratrol [97–99], oleuropein [100] and others have also shown anti-cancer effects. 
Rosemary extract (RE) from the plant Rosmarinus officinalis, is rich in polyphenols with 
carnosic acid (CA), rosmarinic acid (RA), and carnosol (COH) found in high concentrations 
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[95]. RE and RE polyphenols have been reported to have antioxidant and antimicrobial 
properties [101]. A limited number of studies have found that in various breast and prostate 
cancer cells rosemary extract can decrease cell viability, inhibit cell proliferation, induce 
apoptosis, and enhance the effects of various chemotherapeutic drugs [102–105]. 
 
1.10 Anti-cancer Effects of Rosemary Extract (Rosmarinus Officinalis L.) 
1.10.1 Anti-cancer Effects of Rosemary Extract in Breast Cancer: in vitro studies  
The anti-cancer effects of RE in breast cancer have been studied in vitro and it has been 
shown that in MCF-7 (ER+) and MDA-MB-231 (TN) cell lines using supercritical CO2 extracted 
rosemary extract decreased cell viability in a dose dependent manner, with an IC50 value of 20.42 
µg /mL [102]. In comparison, treatment of breast cancer cell lines with rosemary extract 
obtained from dried rosemary leaves using the supercritical fluid extraction technique showed 
that 24 hour supercritical fluid rosemary extract (SFRE) treatment decreased cell viability in five 
breast cancer cell lines [103]. MCF-7 and UACC-812 were most resistant at higher doses of 
SFRE, whereas HER-2 positive was most sensitive at low concentrations. It was also found that 
apoptosis was induced in a dose dependent manner by SFRE in T47D and SK-BR-3 cell lines 
[103]. However, there was an absence of cleaved PARP1 in the treated breast cancer cell lines, 
indicating that SFRE may induce apoptosis though a different pathway. SFRE was also found to 
be more effective on estrogen receptor (ER+) cell lines as it significantly modulated 14 genes in 
these cell lines compared to 4 genes in ER negative cell lines. It is interesting to note that SFRE 
downregulated the expression of ESR1, a gene that encodes for ERα [103]. Similarly, SFRE was 
found to downregulate the HER-2 gene in HER-2 positive breast cancer cell lines [103]. In 
addition, SFRE enhances the antitumor effect of breast cancer chemotherapy drugs including 
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paclitaxel, trastuzumab, and tamoxifen. The combination of the extract with these 
chemotherapeutics showed a significant increase in anti-tumor activity when compared to 
chemotherapeutic drugs alone [103]. Using the methanol extraction method, rosemary extract 
was used to treat MDA-MB-453 (ER-), MDA-MB-468 (TN) and MCF7 (ER+) cell lines for 48 
hours [106]. It was also found that HER-2 positive cell lines were more sensitive to treatment 
with RE as the IC50 value of HER-2 negative treated cells was 25 µg/mL compared to the IC50 
value of the HER-2 positive treated cells, which was 9 µg/mL [106]. Furthermore, treatment with 
various concentrations of rosemary extract (1-100 µg/mL) for 48 hours resulted in an inhibition 
of MCF-7 breast cancer cell proliferation by 44.86% [107]. Rosemary extract inhibited cell 
proliferation in a dose-dependent manner, with an IC50 value of 16.60 µg/mL [107]. 
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Table 1: Anticancer effects of RE and RE polyphenols in vitro: breast cancer. 
Cancer  
Cell 
Polyphenol Dose/ 
Duration 
 
Findings Mechanism Ref 
MDA-MB-231 
 
MCF-7 
 
 
RE 
 
CA 
 
RA 
6.25, 12.5, 
25, 50, 100 
µg/mL RE 
(48 h)  
 
6.25, 12.5, 
25, 50, 100 
µM  
CA and RA 
(48 h) 
CA 50% inhibition 
of MCF-7 at 24.2 
µM concentration. 
 
2-fold higher 
response in  
MDA-MB-231. 
CA causes arrest 
of G2/M phase 
cell cycle 
affecting cyclin. 
 
RA showed 
proliferative 
effects. 
 
Combination of 
TNF-α and RA 
induced 
apoptosis. 
 
[102] 
MDA-MB-231 
 
MCF-7 
 
T-47D 
 
UACC-812 
 
SK-BR-3 
 
CCD-812 
Supercritical 
fluid 
rosemary 
extract 
(SFRE) 
 
Containing 
CA (19.56%) 
and  
COH 
(1.90%) 
50 µg/mL 
(24 h) 
Antitumor activity 
against breast 
cancer cells. 
 
Downregulation of 
ER- α and HER2 
receptors. 
 
SFRE enhanced 
the effect of breast 
cancer 
chemotherapy. 
SFRE decreased 
cancer cell 
viability in a 
dose-dependent 
manner. 
 
MCF-7 and 
UACC-812 cells 
were most 
resistant at 
higher doses. 
 
SFRE dose 
dependently 
induced 
apoptosis in  
T-47D and  
SK-BR-3 cells. 
 
[103] 
MDA-MB-231 
 
MCF-7  
 
CA  
(93%) 
2.5, 5, 10, 
20, 40 
µg/mL 
(24 & 48 h) 
CA inhibits cell 
viability, IC50 
were 8.5 and 
14.02 µg/mL for 
MDA-MB-321 
and MCF-7, 
respectively. 
CA has a 
chemotactic 
ability within 
the generated 
concentration 
gradients. 
[108] 
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Indicates 
selectivity of CA 
for estrogen 
independent cell 
lines. 
 
MCF-7 
 
T47D 
 
MCF-10A 
 
CA 
(98%) 
0, 1, 2.5, 5, 
10, 20, 40 
µM (24 h)  
 
CA showed no 
significant anti-
cancer role in 
T47D cells. 
 
CA alone 
significantly 
down-regulated 
MCF-7 cells in a 
dose dependent 
manner. 
 
CA and tamoxifen 
combined therapy 
significantly 
suppressed cancer 
cell proliferation. 
 
Caspase 3/ 
TRAIL 
activation. 
 
Anti-apoptotic 
Bcl-xL and  
Bcl-2 were 
downregulated. 
 
Pro-apoptotic 
signals Bax and 
Bad were up-
regulated. 
 
[109] 
MCF-7 RA  RA inhibited DNA 
methyltransferases 
(DNMT) activity 
(up to 88% 
inhibition) 
RA reduced 
DNMT protein 
levels. 
 
RA reduced 
PARG activity. 
[110] 
MDA-MB-361 
 
MDA-MB-453 
RA 
(In an extract 
with other 
compounds) 
0, 2, 4, 8, 
10, 20 
µL/mL  
(72 h) 
Significantly 
decreased cell 
survival. 
 
Induced apoptosis 
in a dose-
dependent manner. 
 
 [111] 
MCF-7 RA 1, 5, 10, 20 
µM/L 
Prevent COX-2 
activation by AP-1 
inducing agents in 
 MCF-7. 
RA antagonized 
ERK1/2 
activation. 
[112] 
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Treatment with 
RA alone 
reduced basal 
recruitment of  
c-Jun and c-Fos 
 
MDA-MB-231 COH 25, 50, 100 
µM  
(24 & 48 h) 
Decreased cellular 
viability in a dose 
dependent manner. 
 
COH induced 
apoptosis through 
the intrinsic and 
extrinsic 
pathways. 
 
COH inhibited 
colony growth. 
Induced G2 
phase cell cycle 
block. 
 
Cleaved PARP, 
caspase 3,8,9 
increased in 
concentration in 
a dose- 
dependent 
manner  
(50-100 µM). 
 
Increase in 
Bax/Bc1-2 ratio 
in favour of 
apoptosis 
induction. 
 
[113] 
MDA-231 
 
HBL-100  
 
MCF-7 
 
MDA-361 
  
MDA-345 
COH 12.5, 25, 50, 
100, 200 
µM 
(24, 48, & 
72 h) 
Viability of all cell 
lines inhibited by 
COH in a dose-
dependent manner. 
 
No effect at 
concentration 
lower than 25 µM. 
 
COH suppresses 
the adhesion of 
cancer cells to 
fibronectin in a 
dose-dependent 
manner. 
 
Cells treated with 
COH + curcumin 
maintained in 
Reduced cyclin 
D1 expression 
and induced 
cleavage of 
ROCK1 
(molecule that 
had an apoptotic 
effect on cells). 
[114] 
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suspension 
showed greater 
sensitivity to 
carnosol. 
 
MDA-MB-453  
 
MDA-MD-468 
 
MCF7  
 
 
RE 
 
CA 
 
RA 
0-80 µg/mL CA inhibits breast 
cancer cell 
growth. 
 
RA exerts little 
effects. 
 
The presence of 
HER-2 increased 
the activity of CA. 
 
RE and CA arrest 
the cell cycle at 
the G1 phase at 
low 
concentrations, 
and at the G2 
phase at high 
concentrations. 
 
CA synergizes 
with curcumin in 
triple negative 
breast cancer cells.  
 
CA induces anti-
inflammatory, 
oxidoreductase, 
apoptosis, and 
gluthathione 
metabolism 
genes and 
represses 
inhibitors of 
transcription and 
cell cycle genes. 
 
CA and 
curcumin (as 
well as 
digitoxin) 
inhibit the 
activity of the 
purified Na+/K+ 
ATPase. 
[106] 
MCF-7 RE 1-100 
µg/mL 
(48 h) 
Inhibited MCF-7 
cell proliferation 
by 44.86% 
in a dose 
dependent manner 
 (IC50 = 16.60 
µg/mL). 
 
 [107] 
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1.10.2 Anti-cancer Effects of Rosemary Extract in Breast Cancer: in vivo animal 
studies  
The anti-cancer effects of RE in breast cancer were also studied in vivo. Intraperitoneal 
injections of RE and carnosol at 200 mg/kg for 5 days in female rats inhibited the 7,12-
Dimethylbenz(a)anthracene (DMBA)-induced mammary adduct formation (44% and 40%, 
respectively) [115]. Furthermore, administration of CA to mice inoculated with ER positive 
breast cancer cells resulted in a significant inhibition of tumor growth [109]. Treatment of these 
mice with carnosic acid and tamoxifen (30 and 10 mg/kg, respectively) as a combined therapy 
resulted in a greater inhibition of tumor growth in comparison to carnosic acid or tamoxifen 
monotherapy [109].  
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Table 2: Anticancer effects of RE and RE polyphenols in vivo: breast cancer. 
Animal  
Model 
Polyphenol Dose/ 
Duration 
 
Findings Mechanism Ref 
DMBA-
induced 
mammary 
tumorigenesis 
(Sprague 
dawley rats) 
RE 
 
COH 
Intraperitoneal 
injections 200 
mg/kg for 5 
days. 
Inhibited 
DMBA-
induced 
mammary 
adduct 
formation (44 
and 40% with 
RE and COH 
treatment, 
respectively. 
 
Both COH and 
RE effective 
are inhibitors 
of initiation 
state DMBA-
induced rat 
mammary 
tumorigenesis. 
 
May be due to 
stimulation of 
liver 
detoxification of 
DMBA. 
 
[115] 
MCF-7 
xenograft 
model 
(Athymic nude 
mice) 
CA  30 mg/kg CA 
or 10 mg/kg 
tamoxifen or 
combined. 
Inhibition of 
tumor growth, 
both as 
monotherapies, 
or as a 
combined 
therapy. 
However, 
combined 
therapy 
showed  
greater 
inhibition. 
 
 [109] 
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1.10.3 Anti-cancer Effects of Rosemary Extract in Breast Cancer: ex vivo study 
Cultured breast tumor explants were obtained from precision-cut breast tumor slices from 
eleven patients during surgery at the Hospital of Gynecology and Obstetrics from the Mexican 
Institute of Social Security [116]. The tumor slices were cultured and exposed to varying 
concentrations of the RE polyphenol rosmarinic acid alone, as well as in combination with the 
chemotherapeutic agent paclitaxel [116]. It was found that at RE had no effect at concentrations 
of 60 µg/mL or lower so treatment was increased to 120 µg /mL for 48 hours [116]. At this 
concentration, the effect of RA as a monotherapy did not decrease cell viability or proliferation. 
However, RA as a combination therapy with paclitaxel induced a significant 2.34 fold increase in 
cytotoxicity compared to the untreated control. Therefore, RE and RE polyphenols may have the 
potential to act as a combined therapy with current chemotherapeutic agents to increase their 
effect [116]. 
 
Table 3: Anticancer effects of RE ex vivo: breast cancer. 
Tissue Polyphenol Dose/ 
Duration 
Findings Mechanism Ref 
Breast 
Tumor 
explants 
RA 120 µg /mL  
(48 h) 
Enhanced activity 
of 
chemotherapeutics 
(paclitaxel). 
 
 
 
[116] 
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1.10.4 Anti-cancer Effects of Rosemary Extract in Prostate Cancer: in vitro studies  
The effect of rosemary extract in prostate cancer cells has been studied in vitro and it has 
been found that in PC-3 and DU145 prostate cancer cells, treatment with supercritical CO2 
extracted rosemary decreased cell viability in a dose-dependent manner [102]. Cells were treated 
with various concentrations of RE for 48 hours and the results showed that the supercritical fluid 
extract displayed a greater inhibitory effect compared to the soxhlet extracts in the DU145 
prostate cancer cell line [102]. Similarly, it has also been found that 48 hour RE treatment can 
also inhibit cell viability in 22RV1 and LNCaP prostate cancer cell lines in a dose-dependent 
manner [117]. IC50 values of 13.3 µg/mL and 27 µg/mL were observed for 22RV1 and LNCaP 
cells, respectively [117]. It was also shown that RE inhibited cell proliferation in 22RV1 and 
LNCaP cells by 76.5 and 94.6%, respectively [117]. Concentrations as low as 20 µg/mL of RE 
decreased AR expression and a significant decrease in PSA was shown in LNCaP cells [117]. 
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Table 4: Anticancer effects of RE and RE polyphenols in vitro: prostate cancer. 
 
Cancer 
Cell 
Polyphenol Dose/ 
Duration 
Findings Mechanism Ref 
PC-3 
 
DU145 
 
RE 
 
CA 
 
RA 
6.25, 12.5, 
25, 50,100 
µg/mL 
(48 h)  
 
18.8-150 µM 
CA (48 h) 
 
17.3-138.8 
µM RA  
(48 h) 
Decrease in cell 
viability (IC50 = 
8.82 µg/mL for 
RE treatment). 
 
 [102] 
LNCaP 
22RV1 
RE  10-50 µg/mL 
(24 to 48 h) 
 
RE 
standardized 
to 40% CA. 
Decrease in cell 
viability and 
proliferation. 
 
Increase in cell 
cycle arrest and 
apoptosis. 
 
Increase CHOP, 
BAX, and cleaved 
caspase 3. 
 
Decrease PSA 
production and 
androgen receptor 
expression. 
[117] 
PC-3 CA 20-100 µM 
(0-72 h) 
Decreased cell 
proliferation. 
 
Increased 
apoptosis. 
Decreased caspase 
8, 9, Bcl-2, Bid, 
IAP, p-Akt, p-
GSK3, and NF-
kB. 
 
Increased Caspase 
3, 7, PARP 
cleavage, Bax, 
Cytochrome c, and 
PP2A. 
[118] 
PC-3 
 
LNCaP 
 
DU145 
CA 10 µM  
(72 h) 
Decreased cell 
proliferation. 
Decreased 
EpRE/ARE 
transcription 
system. 
 
Decreased PSA 
secretion. 
[119] 
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LNCaP 
 
22RV1 
CA 10-100 µM 
(24 to72 h) 
Decreased cell 
proliferation and 
viability. 
 
Increased 
apoptosis. 
Decreased 
expression of 
PSA. 
 
Increased cleaved 
caspase 3 
expression. 
[120] 
 
1.10.5 Anti-cancer Effects of Rosemary Extract in Prostate Cancer: in vivo animal 
studies  
The anti-cancer of RE in prostate cancer using an in vivo model showed that treatment of 
athymic nude mice transplanted with 22RV1 human prostate cancer cells with RE [117] and CA 
[120] resulted in decreased tumor size. Athymic nude mice were treated with either olive oil or 
RE dissolved in olive oil for 22 days [117]. Tumor formation was observed at day 14 and by the 
end of the study period a 46% reduction in tumor size was measured in the RE administered 
mice when compared to the control [117]. Western blots using lysates from the mouse tissue 
showed decreased AR and PSA expression in the RE treated group compared to the untreated 
control [117]. Similarly, athymic nude mice treated with CA dissolved in cotton seed oil for 25 
days showed a 53% reduction in tumor growth when compared to the control untreated mice 
[120]. CA also decreased AR expression, as determined by western blotting control [120].  
Although the studies examining the effects of rosemary extract and rosemary extract 
polyphenols in vivo are limited, the data/evidence suggest they may be effective in inhibiting 
tumor growth as a monotherapy or as a combined therapy with other chemotherapeutic agents. 
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Table 5: Anticancer effects of RE and RE polyphenols in vivo: prostate cancer. 
Animal 
Model 
Polyphenol Dose/ 
Duration 
Findings Mechanism Ref 
22RV1  
xenograft 
model 
(Athymic nude 
mice) 
RE 100 
mg/kg/day in 
olive oil, 
orally  
(22 days) 
Decreased 
tumor 
volume 
(induced 
apoptosis). 
Decreased 
androgen 
receptor 
expression and 
PSA. 
 
Increased 
CHOP. 
[117] 
22RV1  
xenograft 
model 
(Athymic nude 
mice) 
CA 100 
mg/mouse 
dissolved in 
100 µL of 
cottonseed oil 
by oral 
gavage  
(25 days) 
 
53% 
reduction in 
tumor 
growth. 
 [120] 
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Chapter 2: Rationale, Objectives and Hypotheses of the Present 
Study  
2.1 Rationale  
 It has been well established that cancer cells have enhanced proliferative and survival 
capabilities. These capabilities are the result of mutations in key signaling proteins including 
ones involved in the PI3K/Akt and Ras/MAPK pathways as discussed in Chapter 1. Many 
chemotherapeutic agents have been discovered to specifically target these proteins, however due 
to drug resistance, over time chemo and radio-therapies become ineffective. The discovery of 
novel chemicals that can be used alone or in combination with existing drugs to treat cancer, 
especially those that are highly aggressive, is essential to improve patient outcome.  
 Breast and prostate cancer are the most frequently diagnosed cancers in women and men 
respectively, in North America [1,2]. TNBC accounts for over 15% of all breast cancer cases and 
represents an aggressive form of the disease, with limited treatment options, and poor prognosis 
[30,36]. Due to the absence of estrogen receptor, progesterone receptor, and HER-2 
amplification, TNBCs do not benefit from hormone-based therapies [36].  
Prostate cancers that do not express PSA and are androgen-independent are highly 
aggressive and do not respond well to hormone-based therapies [121]. This highlights the 
necessity to develop new therapeutic strategies to treat breast and prostate cancer. 
The Mediterranean diet has long been attributed to preventing or delaying the onset of 
cardiovascular disease, diabetes, and various cancers. One component of this diet that is 
commonly used is the herb rosemary. Rosemary extract from the plant Rosmarinus officinalis, is 
rich in polyphenols with carnosic acid, rosmarinic acid, and carnosol found in high 
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concentrations [95]. RE and RE polyphenols have been reported to have antioxidant and 
antimicrobial properties [101].  Rosemary extract has also shown to exert anti-cancer effects both 
in vitro and in vivo across various types of cancers [95]. Limited data exists regarding the effects 
of rosemary extract in TNBC and prostate cancer, and little is known about the underlying 
signaling mechanisms involved in its anti-proliferative properties.  
Historically, many plants and food components have been the basis for isolation of 
compounds that are used in the treatment of various illnesses. Acetylsalicylic acid (Aspirin), 
commonly used to treat minor pain and reduce inflammation, was isolated from the willow tree, 
and morphine, used to treat pain, is an opioid isolated from the opium poppy. Recently, plant 
derived extracts with high polyphenolic content such as green tea [93], rosemary extract [95], as 
well as individual polyphenols such as quercetin [96], resveratrol [97,98], oleuropein [100] and 
others have also shown anti-cancer effects. Thus, further investigation of rosemary may lead to 
the discovery of chemicals with potent anticancer properties.  
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2.2 Objectives  
The objectives of the present study were to:  
a) Examine the effects of rosemary extract on proliferation, survival, and migration in 
MDA-MB-231 triple negative breast cancer and PC-3 prostate cancer cells. 
 
b) Investigate the effects of RE on key signaling proteins involved in the pathways that 
regulate cell proliferation, survival/apoptosis, and migration. 
 
2.3 Hypotheses  
In the present study it was hypothesized that:  
a) Rosemary extract inhibits cell proliferation, survival, and migration of MDA-MB-231 
triple negative breast cancer and PC-3 prostate cancer cells in a dose-dependent 
manner.  
 
b) Rosemary extract modulates the signaling cascades involved in regulating cell 
proliferation and survival/apoptosis in MDA-MB-231 breast and PC-3 prostate cancer 
cells.  
 
i. RE inhibits the PI3K/Akt and Ras/MAPK pathways, as well as induce 
apoptosis by increasing PARP cleavage.  
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Chapter 3: Methodology  
3.1 Cell Lines  
 Cells in culture were used to investigate the anticancer effects of rosemary extract and its 
main polyphenolic constituents. These cells resemble the primary tumor population but offer a 
homogenous population of cells with unlimited replicative capacity. The use of cultured cells to 
investigate the physiology and biochemistry of cells and intracellular signaling pathways is well-
established. The cell lines to be used in this study are the triple negative breast cancer cells 
(MDA-MB-231) and androgen insensitive prostate cancer cells (PC-3). These cells will be used 
for experiments in vitro and detailed cellular mechanisms/pathways elucidated. 
The MDA-MB-231 cell line was isolated from pleural effusions of a 51-year-old female 
Caucasian with breast cancer [122]. This cell line does not express estrogen receptors and 
therefore has been widely used to examine non-hormone sensitive breast cancer. 
The PC-3 cell line was derived from a 62-year-old Caucasian male from the bone metastasis of a 
grade IV prostatic adenocarcinoma [123]. These cells do not express the androgen receptor and 
therefore are a widely used in vitro model of hormone insensitive prostate adenocarcinoma. 
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Table 6: Breast/prostate cancer cell line properties. 
 
Cell Line 
 
Histology 
 
Mutation Status/ Hormone Responsiveness 
 
MDA-MB-231 
 
Breast adenocarcinoma 
p53 null 
KRAS mutation 
Estrogen/ progesterone receptor negative 
Human epidermal growth factor receptor-2 
negative 
 
PC-3 
 
Prostate adenocarcinoma 
p53 null 
PTEN null  
Androgen insensitivity  
Prostate specific antigen negative 
 
3.2 Materials 
The MDA-MB-231 (adenocarcinoma) and PC-3 (adenocarcinoma) cancer cells were 
obtained from American Type Culture Collection (ATCC) (Virginia, USA). The Dulbecco’s 
Modified Eagles Medium (DMEM), fetal bovine serum (FBS), 0.25% trypsin and the antibiotic-
antimycotic solution were purchased from GIBCO Life Technologies (Burlington, ON, Canada). 
Akt (#9272) (1:1000 dilution), p-Akt (Ser473) (#9271) (1:1000 dilution), mTOR (#2972) 
(1:1000 dilution), p-mTOR (#2971) (1:1000 dilution), PARP (#9542) (1:1000 dilution), -actin 
(#8457) (1:1000 dilution), as well as secondary anti-rabbit IgG HRP-linked antibodies (#7074) 
(1:2000 dilution) were from Cell Signaling Technology via New England Biolabs (Mississauga, 
ON, Canada). Bovine serum albumin (BSA), dimethyl sulfoxide (DMSO), Paclitaxel, and 
Metformin were from Sigma (Oakville, ON, Canada). Clarity Western enhanced 
chemiluminescence substrate (ECL), 30% acrylamide/bis solution 37 (5:1), ammonium 
persulfate (APS), polyvinylidene difluoride (PVDF) membranes and reagents for electrophoresis 
were purchased from Bio-Rad (Hercules, CA, USA). 
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3.3 Buffers and Solutions  
The buffers and solutions that will be required for each experiment and their compositions are 
provided below:  
 
Cell Lysis 
Phosphate Buffered Saline (PBS) Solution- Wash Buffer 
137 mM NaCl; 2.7 mM KCl; 1.5 mM KH2PO4; 8.1 mM Na2HPO4; 0.68 mM CaCl2; 0.49 mM 
MgCl2; Add distilled water to achieve final volume, adjust pH to 7.4 and sterilize (autoclave) 
before use. 
 
Cell Lysis Buffer 
20 mM Tris-HCl solution (pH 7.5); 150 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1% Triton X-
100; 2.5 mM Na4P2O7; 1mM glycerol 2-phosphate; 1 mM Na3VO4; 1 μg/mL leupeptin; add 1 
mM PMSF before use and chill on ice. 
 
4X SDS Sample Buffer 
240 mM Tris-HCl solution (pH 6.8); 8% w/v SDS; 40% glycerol, 0.04% bromophenol blue; 
deionized water; add 5% β-mercaptoethanol before use. 
 
Western blotting solutions 
1.5 M Tris-HCl (pH 8.8) 
27.23g Tris base (18.15 g/100 mL); 80 mL deionized water; adjust pH to 8.8 with 6 N HCl and 
bring total volume to 150 mL with deionized water 
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0.5 M Tris-HCl (pH 6.8) 
6 g Tris base (6 g/100 mL); 60 mL deionized water; adjust pH to 6.8 with 6 N HCl and bring 
total volume to 100 mL with deionized water. 
 
Resolving Gel Buffer (10%) – for 4 1.5 mm gels 
12.3 mL deionized water; 9.9 mL 30% acrylamide/Bis solution; 7.5 mL 1.5 M Tris-HCl (pH 
8.8); 0.3 mL 10% w/v SDS. Right before pouring gel add 150 μL 10% APS (0.01 g into 100 μL 
deionized water) made fresh daily and 30 μL TEMED and swirl. 
 
Stacking Gel Buffer (4%) – for 4 1.5 mm gels 
18.3 mL deionized water; 3.9 mL 30% acrylamide/Bis solution; 7.5 mL 0.5M Tris-HCl (pH 6.8); 
0.3 mL 10% w/v SDS. Right before pouring gel add 150 μL 10% APS (0.01 g into 100 μL 
deionized water) made fresh daily and 30 μL TEMED and swirl. 
 
10x Tris-Buffered Saline (TBS) 
24.2 g Tris base; 80 g NaCl; fill to total volume of 1 L with deionized water; adjust pH to 7.6 
with HCl. Use as 1x TBS/T (50 mL 10x TBS into 450 mL deionized water; then add 500 μL 
Tween). 
 
10x Electrode Running Buffer 
15.15 g Tris base; 72 g glycine; 5 g SDS; dissolve and bring volume to 500 mL with deionized 
water. Do not adjust pH. Before use dilute to 1x (50 mL 10x stock into 450 mL deionized water). 
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Wash Buffer 
1x TBS and 0.1% Tween-20. 
 
Transfer Buffer 
25 mM Tris base (3.03 g); 0.2 M glycine (15.01 g); 20% methanol (200 mL/800 mL deionized 
water); adjust final volume to 1 L. 
 
Blocking Buffer 
15 mL 10x TBS; 135 mL deionized water; 7.5 g nonfat dry milk (5% w/v); 0.15 mL Tween; 
make fresh each time. 
 
Primary Antibody Dilution Buffer 
2 mL 10x TBS; 18 mL deionized water; 1.0 g BSA; 20 μL Tween (add after first 3 ingredients 
are mixed); add 10 μL primary antibody before use. 
 
Secondary Antibody Buffer 
10 mL blocking buffer; 5 μL secondary antibody; make fresh each time. 
 
Crystal violet assay solutions 
Crystal Violet Stain 
0.5% w/v crystal violet stain in 25% v/v methanol; keep solution covered from light 
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Solubilizer Solution 
0.05 M NaH2PO4 (MW 119.98 g/mol) in 50% v/v ethanol; keep solution covered from light 
 
Wound healing assay solution 
Mitomycin-C 
1 g/mL mitomycin-C prepared in RPMI or DMEM media. 
 
3.4 Cell Culture  
 MDA-MB-231 are epithelial breast adenocarcinoma cells. The MDA-MB-231 breast 
cancer cells were cultured in DMEM media supplemented with 1% (v/v) antibiotic- antimycotic 
(100 µg /mL penicillin, 100 µg/mL streptomycin and 250 ng/mL amphotericin) and 10% (v/v) 
FBS. PC-3 are epithelial prostate adenocarcinoma cells. The PC-3 prostate cancer cells were 
cultured in RPMI 1640 media supplemented with 1% (v/v) antibiotic- antimycotic (100 µg /mL 
penicillin, 100 µg/mL streptomycin and 250 ng/mL amphotericin) and 10% (v/v) FBS. Media 
was changed every 2-3 days and cells were trypsinized with 0.25% trypsin EDTA when 70-80% 
confluency was achieved. Cells were grown in an incubator at 37℃ and 5.0% carbon dioxide 
(CO2)- 95% air. Cell handling was performed in Forma Class II, A2 Biological Safety Cabinet. 
 
3.5 Rosemary Extract Preparation  
 
Whole dried rosemary (Rosmarinus officinalis L.) leaves (purchased from 
Compliments/Sobeys, Mississauga, ON, Canada) were used, and the rosemary extract was 
prepared as previously reported [124]. Briefly, dried rosemary leaves were ground and steeped 
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overnight (16 hours) in dichloromethane: methanol (1:1) followed by filtration the next day. 
After filtering, the liquid solvent was set aside while the leaves were boiled in methanol for 30 
minutes. The liquid solvent obtained after boiling was combined with the filtered liquid solvent. 
The combined solvent was removed from the final extract by rotary evaporation and the green 
powder was collected and stored at -20 ̊C, protected from light. Aliquots were prepared in 
dimethyl sulfoxide (DMSO) to yield a final concentration of 100 mg/mL. 
 
3.6 Crystal Violet Assay  
The crystal violet assay was used to assess cell proliferation/ growth. The crystal violet 
binds and stains the DNA of the cells, thus allowing for the measurement of the cells ability to 
divide after exposure to a specific treatment. Cells were seeded (1000; counted using 
hemocytometer) in 100 µL supplemented DMEM or RPMI 1640 media in triplicate wells in 96-
well plates and allowed to adhere overnight. The following day, treatments were added with an 
extra 100 µL media, with a final volume of 200 µL, and was incubated for 72 hours. After the 72 
hour time course, the media was removed, and the cells were fixed with 10% formalin (100 µL 
per well). The wells were then rinsed using sterile 1X phosphate buffered saline (PBS) and 
stained using 0.5% crystal violet stain in 25% v/v methanol (50 µL/ well). The excess stain was 
removed by submerging the plates three times in tap water, and the plates were then allowed to 
dry overnight. The next day solubilizer solution composed of 0.05 M NaH2PO4 in 50% v/v 
ethanol was added (100 µL/well) and absorbance was read at 570 nm using the KC4 microplate 
reader. 
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3.7 Clonogenic Survival  
The clonogenic assay was used to assess the colony forming abilities of the cells, which 
is an enhanced characteristic of cancer cells, enabling the formation of tumors and allows the 
cancer to become more aggressive. Cells were seeded (1000; counted using hemocytometer) in 
duplicates in 2 mL supplemented in 6-well plates and allowed to adhere for 24 hours. The 
following day, the media was removed, and treatments were added (2 mL per well) and the cells 
were maintained in the incubator for seven days. At the end of the time course, the media was 
aspirated, and cells were washed twice with sterile 1X phosphate buffered saline (PBS) and then 
stained with 0.05% w/v methylene blue in distilled water. Cells were stained for 15 minutes, the 
excess stain was recovered, and the cells were left on the counter to dry overnight. The next day, 
colonies greater than 50 cells were counted under the microscope. 
 
3.8 Wound Healing Assay  
The wound healing assay was used to assess the migration abilities of the cells. The 
migrating ability of the cells may indicate the capabilities of the cells to metastasize. Cells were 
seeded at a density of 2.5 x 105 cells/mL into a 6-well plate and the media was replaced every 48 
hours until the cells reached 90-100% confluency. When confluency was reached the cells were 
incubated with mitomycin-C (MMC) (1 g/mL) for 1 hour to prevent cell proliferation. After the 
incubation period, a vertical line is drawn in the centre of each well using a 100 L pipette tip. 
The wells were drained of media and washed twice with PBS to get rid of floating cells. Each 
well was then treated with rosemary extract and paclitaxel, respectively. Before taking 
photographs, horizontal lines were drawn underneath the well plates to be used as a reference for 
future time points. Photos were taken at 0 and 40-hour time points. Wound closure percentage 
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was calculated using the equation  
0hr Area—40 hr Area
0 Hr Area
 x 100%. The area of each wound was 
measured using the ImageJ software.   
 
3.9 Cell Lysis  
Cells were seeded in triplicate in 6-well plates and maintained in the incubator until 90-
100% confluency was achieved. MDA-MB-231 cells were serum deprived prior to being 
exposed to treatments, all cells were serum deprived for 48 hours total. Cells were treated with 
50 µg/mL of rosemary extract for the indicated time-period in 10% FBS containing media. 
Following treatment, cells lysis was performed using cell lysis buffer which contained 
phenlymethylsulfonyl fluoride (PMSF) protease inhibitor (150 µL/well) and scraped with a 
plastic scraper. The lysates were then pipetted into 1.5 mL Eppendorf tubes and 50 µL was 
removed to be used for the protein assay. Lysates were dyed using 4x SDS sample buffer by 
adding 1:4 ratio of dye to lysate. Samples were then boiled for 5 minutes and stored in -20 ℃.  
 
3.10 Protein Assay  
The protein assay was performed to determine the correct loading volume of each sample 
to be used in western blotting. Cell lysate samples were pipetted in triplicates into a 96-well plate 
(10 µL/well) as well as 200 µL/well of Bio-Rad protein assay dye reagent (1:4 dye reagent: 
distilled water). Samples were incubated for 5-10 minutes and absorbance was measured at 595 
nm using the KC4 microplate reader. The samples absorbance as compared to the standard 
absorbance in order to calculate the final protein concentrations in the samples. 
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3.11 Western Blotting  
Western blotting is a technique used to examine the inhibition or activation of specific 
signaling cascades by measuring the total and phosphorylated levels of proteins of interest, such 
as Akt or mTOR. Cell lysate samples containing 20 µg of protein, determined using the Bradford 
assay [125], were loaded onto 10% polyacrylamide gel and separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). The separated proteins were then transferred 
onto polyvinylidene difluoride (PVDF), membrane which was exposed to blocking buffer (5% 
(w/v) dry milk in Tris-buffered saline) for 1 hour and incubated with the primary antibody 
overnight at 4C. The following day the membrane was incubated with horse radish peroxidase 
(HRP)-linked IgG anti-rabbit secondary antibody for 1 hour at room temperature. Enhanced 
chemiluminescence (ECL), the Bio-Rad Clarity Western solution, was used to detect the bands 
corresponding to the proteins of interest. Densitometric analysis was performed using ImageJ 
software. The data (arbitrary densitometric units) were corrected to -actin levels and expressed 
as a percentage of untreated control cells.  
 
3.12 Statistical Analysis  
The results are the mean ± standard error mean (SEM) of the indicated number of 
independent experiments. Analysis of Variance (ANOVA) followed by Bonferroni’s post-hoc 
test was used to determine the significance of the differences between groups. Statistical 
significance was assumed at p<0.05. Statistical tests were performed using GraphPad Prism 8 
software. 
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Chapter 4: Results 
4.1 Biological effects of rosemary extract (RE) in triple negative breast cancer cells 
4.1.1 Effects of RE on cell proliferation in MDA-MB-231 breast cancer cells  
The triple negative MDA-MB-231 breast cancer cells were exposed to 10, 20, 30, 40, 50, 
75, or 100 µg/mL RE for 72 hours and cell proliferation was assessed using the crystal violet 
assay. Treatment with RE resulted in a dose–dependent inhibition of cell proliferation. A 
significant inhibition (83.95 ±1.96 % of control, p<0.0001) was seen with 20 µg/mL RE while 
maximum inhibition (34.79 ±2.32 % of control, p<0.0001) was seen with 50 µg/mL RE (Figure 
4A and B). Higher RE concentrations (75 and 100 µg/mL) did not result in any greater inhibition 
of cell proliferation (Figure 4A). The IC50 of RE for cell proliferation was 28.86 µg/mL. 
Previous studies by our group [92,126] and others [127,128] have shown anticancer effects of 
metformin, a drug used to treat hyperglycemia /type 2 diabetes mellitus [129], and therefore, 
metformin was used in the present study to compare its effects with the effects of RE. In 
addition, paclitaxel, derived from Taxus brevifolia is an established medication used clinically in 
the treatment of triple negative breast cancer [130] and we used it in the present study to 
compare the effects of RE to the effects of paclitaxel. Treatment of the cells with 5 mM 
metformin did not result in any significant inhibition of cell proliferation (100.5 ±2.10% of 
control) (Figure 4B), while treatment with 10 nM of paclitaxel showed significant inhibition of 
cell proliferation (72.31 ±10.77% of control, p<0.01) (Figure 4B). Importantly, the inhibition of 
cell proliferation seen with 50 µg/mL of rosemary extract (34.79 ±2.32 % of control, p<0.0001) 
was greater than that seen with 10nM of paclitaxel (72.31 ±10.77% of control, p<0.01).  
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(A) 
 
(B) 
 
Figure 4. Effect of rosemary extract on MDA-MB-231 breast cancer cell proliferation. 
MDA-MB-231 cells were treated without (control) or with the indicated concentrations of 
rosemary extract (RE) (A, B), metformin (Met) (B), or paclitaxel (PTX) (B) for 72h followed by 
fixing and staining with 0.5% crystal violet. The stain was solubilized, and absorbance was read 
at 570 nm. Data are the mean ± SEM of 6 independent experiments. **p<0.01, ****p<0.0001. 
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4.1.2 Effects of RE on cell survival in MDA-MB-231 breast cancer cells  
The ability of cancer cells to survive and form colonies was assessed using the clonogenic 
survival assay. Exposure of MDA-MB-231 cells to 2.5, 5, 10, or 25 µg/mL of RE resulted in a 
concentration-dependent inhibition of survival (Figure 5A). The lowest concentration of RE that 
resulted in a significant inhibition of cell survival was 2.5 µg/mL (66.47 ±7.39% of control, 
p<0.001). The greatest inhibition (9.33 ±3.09% of control, p<0.0001) of cell survival was seen at 
25 µg/mL RE (Figure 5B). Based on our data we calculated the RE concentration for the half 
maximal inhibition (IC50) of cell survival was 4.82 µg/mL. Exposure of the cells to 5mM of 
metformin was found to significantly inhibit MDA-MB-231 cell survival (63.36 ±6.01% of 
control, p<0.0001) (Figure 5B). In addition, treatment with 2 nM of paclitaxel resulted in a 
significant inhibition of cell survival (47.28 ±3.13% of control p<0.0001). It should be noted that 
the inhibition of MDA-MB-231 cell survival seen with 25 µg/mL of RE (9.33 ±3.09% of control 
p<0.0001) was much greater than that seen with metformin (63.36 ±6.01% of control, p<0.0001) 
or paclitaxel (47.28 ±3.13% of control, p<0.0001) treatment.   
 
 
 
 
 
 
 
 
Investigation of the Anti-Cancer Effects of Rosemary Extract in Human Breast and Prostate Cancer Cells 
 
 48 
(A) 
 
(B) 
 
Figure 5. Effect of rosemary extract on MDA-MB-231 breast cancer cell survival. MDA-
MB-231 cells were seeded (1000 cells/well) in a 6-well plate and exposed to the indicated 
concentrations of rosemary extract (RE) (A, B), metformin (Met) (B), or paclitaxel (PTX) (B) for 
7 days followed by fixing and staining with 0.05% methylene blue. Colonies of more than 50 cells 
were counted. Data are the mean ± SEM of 6 independent experiments. ***p<0.001, 
****p<0.0001. 
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4.1.3 Effects of RE on Akt signaling in MDA-MB-231 breast cancer cells  
Next, we examined the effects of RE treatment on the activation of the pro-survival kinase 
Akt and measured the levels of Akt phosphorylation on the serine 473 residue, an established 
indicator of Akt activity [131]. Treatment of MDA-MB-231 breast cancer cells with rosemary 
extract (50 µg/mL) for 24 hours (25.62 ±2.56% of control, p<0.0001) and 48 hours (11.05 
±0.62% of control, p<0.0001) resulted in a significant decrease in Akt phosphorylation/activation 
(Figure 6A and 6B). The total Akt levels were also significantly inhibited by RE treatment for 24 
(36.18 ±5.75% of control, p<0.0001) and 48 (18.89 ±5.99% of control, p<0.0001) hour 
treatment. Treatment of MDA-MB-231 cells with paclitaxel for 24 hours also showed a 
significant of inhibition of Akt phosphorylation/activation (50.06 ±14.25% of control, p<0.01). 
Total Akt levels were also decreased with 24 hour RE treatment in MDA-MB-231 cells (82.78 
±4.02% of control, p<0.01). Similarly, treatment of MDA-MB-231 cells with paclitaxel for 48 
hours also resulted in a significant inhibition of Akt phosphorylation/activation (45.59 ±16.47% 
of control, p<0.001) and total Akt levels (80.05 ±8.842% of control, p<0.001) (Figure 6B).  
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Figure 6. Effect of rosemary extract on Akt signaling in MDA-MB-231 breast cancer cells. 
Cell lysates were prepared from MDA-MB-231 breast cancer cells treated without (control) or 
with either 50 µg/mL rosemary extract (RE) or 10 nM paclitaxel for 24 or 48 hours. Cell lysates 
(20 µg) were immunoblotted using specific antibodies against Akt, phosphorylated/activated Akt, 
or -actin. A representative immunoblot is shown (A). The densitometry of the bands were 
corrected to -actin levels and expressed in arbitrary densitometry units as % of control. The data 
are the mean ± SEM of 3 independent experiments. **p<0.01, ***p<0.001, ****p<0.0001.  
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4.1.4 Effects of RE on mTOR signaling in MDA-MB-231 breast cancer cells  
We also examined mTOR phosphorylation/activation levels. Treatment of MDA-MB-231 
cells with RE for 24 hours resulted in a significant decrease in mTOR phosphorylation (20.78 
±3.90% of control, p<0.0001). Additionally, 48 hour RE treatment also resulted in a significant 
inhibition of mTOR phosphorylation/activation (12.49 ±5.04% of control, p<0.0001) (Figure 7A 
and 7B). Treatment with RE for 24 hours significantly inhibited total-mTOR expression (8.11 
±1.32% of control, p<0.0001). Similarly, treatment with RE for 48 hours also inhibited total-
mTOR levels (5.34 ±3.28% of control, p<0.0001). Exposing MDA-MB-231 cells to paclitaxel 
for 24 hours did not result in a statistically significant inhibition of mTOR 
phosphorylation/activation (101.35 ±8.62% of control, p>0.05). A similar trend was also seen for 
48 hour RE treated MDA-MB-231 cells (97.58 ±12.53% of control, p>0.05) (Figure 7B). 
Importantly, RE treatment was able to modulate mTOR expression in these cells at both 
treatment durations.  
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Figure 7. Effect of rosemary extract on mTOR signaling in MDA-MB-231 breast cancer 
cells. Cell lysates were prepared from MDA-MB-231 cells treated without (control) or with either 
50 µg/mL rosemary extract (RE) or 10 nM paclitaxel (PTX) for 24 and 48 hours. Cell lysates (20 
µg) were immunoblotted using specific antibodies against mTOR, phosphorylated/activated 
mTOR or -actin. A representative immunoblot is shown (A). The densitometry of the bands were 
corrected to -actin levels and expressed in arbitrary densitometry units as % of control (B). The 
data are the mean ± SEM of 3 independent experiments. ****p<0.0001. 
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4.1.5 Effects of RE on apoptosis in MDA-MB-231 breast cancer cells  
Next, we examined the effect of RE on cell apoptosis by measuring the levels of cleaved 
PARP, since it is an established indicator of apoptosis [80]. Exposing the MDA-MB-231 cells to 
rosemary extract (50 µg/mL) for 24 and 48 hours resulted in a significant increase in the cleaved 
PARP/PARP ratio (41.4- and 17.5-fold increase, respectively) relative to the control indicating 
enhanced apoptosis (Figure 8A and 8B). Treatment of MDA-MB-231 cells with 10 nM 
paclitaxel for 24 or 48 hours did not result in any changes to the level of cleaved PARP (Figure 
8B).  
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 (A) 
 
(B) 
 
Figure 8. Effect of rosemary extract on MDA-MB-231 breast cancer cell apoptosis. Cell 
lysates were prepared from MDA-MB-231 TN breast cancer cells treated without (control) or 
with either 50 µg/mL RE or 10 nM paclitaxel for 24 or 48 hours. Cell lysates (20 µg) were 
immunoblotted using specific antibodies against PARP or -actin. A representative immunoblot 
is shown (A). The densitometry of the bands were corrected to -actin levels and expressed as a 
fold increase of arbitrary densitometry units as % of control (B). The data are the mean ± SEM of 
3 independent experiments. **p<0.01, ****p<0.0001. 
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We routinely examined microscopically the effect of our treatments on cell morphology. 
Figure 9 shows a representative image of control untreated, RE treated, and PTX treated MDA-
MB-231 cells. No changes in cell morphology were observed with any of the treatments. It 
should be noted that the same number of cells were seeded in all wells. As it can be seen from 
Figure 9, treatment with 50 µg/mL of RE for 24 and 48 hours resulted in a substantial reduction 
of cell density relative to the control untreated groups. Although treatment with PTX for 24 and 
48 hours showed a reduction in cell density, it was not as great as the inhbition seen with RE.  
 
Figure 9. Effect of rosemary extract and paclitaxel on MDA-MB-231 cell morphology. Cells 
were treated without (control) or with RE (50 µg/mL) or PTX (10 nM) for 24 or 48 hours. 
Photographs were taken immediately after treatment (0 hr) and after the inidctaed time points 
using an EVOS XL Core Cell Imaging System by Life Technologies (10X magnification). 
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4.1.6 Effects of RE on MDA-MB-231 breast cancer cell migration  
The ability of cancer cells to migrate was assessed using the wound healing assay [132–
134]. MDA-MB-231 cells were exposed to 1 µg/mL of mitomycin-C (MMC) for 1 hour to 
inhibit cell proliferation and were then treated without (control) or with either 50 µg/mL 
rosemary extract or 10 nM paclitaxel for 40 hours, just before complete wound closure. 
Treatment with rosemary extract was shown to significantly inhibit wound closure (65.15 
±0.97% of control, p<0.001) indicating properties against cell migration (Figure 10B). A 
significant inhibition of cell migration was also seen when treating the cells with 10 nM 
paclitaxel (78.44 ±5.60%, p<0.01) (Figure 10A and 10B). 
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(A) 
 
 
(B) 
 
Figure 10. Effect of rosemary extract on MDA-MB-231 breast cancer cell migration. MDA-
MB-231 cells were exposed to 1 µg/mL of mitomycin-C for one hour, followed by treated without 
or with 50 µg/mL rosemary extract (RE) or 10 nM paclitaxel (PTX) for 40 hrs. Representative 
images of wound healing are shown immediately after being scratched with a 200 µL pipette tip 
(0 hr) and after 40 hours of treatment (A). Wound closure was calculated as indicated in the 
methods and expressed as a percent of control untreated cells (B). The data are the mean ± SEM 
of 3 independent experiments. **p<0.01, ***p<0.001. 
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4.2 Biological effects of rosemary extract (RE) in prostate cancer cells 
4.2.1 Effects of RE on cell proliferation in PC-3 prostate cancer cells  
The antiproliferative effects of RE were evaluated in PC-3 cells. The androgen receptor 
negative PC-3 prostate cancer cells were exposed to 5, 10, 25, 50, 75, 100, or 150 µg/mL RE for 
72 hours and cell proliferation was assessed using the crystal violet assay. Treatment with RE 
resulted in a dose–dependent inhibition of cell proliferation. A significant inhibition (80.25 ±4.44 
% of control, p<0.01) was seen with 10 µg/mL RE while maximum inhibition (26.51 ±2.95 % of 
control, p<0.0001) was seen with 50 µg/mL RE (Figure 11A and 11B). Higher RE 
concentrations (75 and 100 µg/mL) did not result in a statistically greater inhibition of cell 
proliferation compared to 50 µg/mL (Figure 11A). The IC50 of RE for cell proliferation was 
19.72 µg/mL. In addition, docetaxel, derived from Taxus baccata and paclitaxel, derived from 
Taxus brevifolia, are established medications used clinically in the treatment of prostate cancer 
[135] and we used them in the present study to compare the effects of RE to the effects of the 
aforementioned chemotherapeutic drugs. Treatment of the cells with 5 nM PTX did not result in 
any significant inhibition of cell proliferation (91.27 ±2.79% of control, p>0.05) (Figure 11B), 
while treatment with 10 nM of paclitaxel showed significant inhibition of cell proliferation 
(67.63 ±4.24% of control, p<0.01) (Figure 11B). Importantly, the inhibition of cell proliferation 
seen with 50 µg/mL of rosemary extract (26.51 ±2.95 % of control, p<0.0001) was greater than 
that seen with both 5 nM (38.11 ±1.16% of control, p<0.0001) and 10 nM DTX (32.08 ±0.84% 
of control, p<0.0001) treatment. 
 
 
 
Investigation of the Anti-Cancer Effects of Rosemary Extract in Human Breast and Prostate Cancer Cells 
 
 59 
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Figure 11. Effect of rosemary extract on PC-3 prostate cancer cell proliferation. PC-3 cells 
were treated without (control) or with the indicated concentrations of rosemary extract (RE) (A, 
B), paclitaxel (PTX) (B), or docetaxel (DTX) (B) for 72h followed by fixing and staining with 
0.5% crystal violet. The stain was solubilized, and absorbance was read at 570 nm. Data are the 
mean ± SEM of 6 independent experiments. **p<0.01, ****p<0.0001. 
0 5 10 25 50 75 10
0
15
0
0
25
50
75
100
RE Concentration (µg/mL)
C
e
ll
 P
ro
li
fe
ra
ti
o
n
 (
%
 C
o
n
tr
o
l)
**** **** ****
****
****
**
Investigation of the Anti-Cancer Effects of Rosemary Extract in Human Breast and Prostate Cancer Cells 
 
 60 
4.2.2 Effects of RE on cell survival in PC-3 prostate cancer cells  
The ability of cancer cells to survive and form colonies was also assessed in PC-3 cells 
using the clonogenic survival assay. Exposure of PC-3 cells to 0.5, 1, 2.5, 5, or 10 µg/mL of RE 
resulted in a concentration-dependent inhibition of survival (Figure 12A). The lowest 
concentration of RE that resulted in a significant inhibition of cell survival was 0.5 µg/mL (80.20 
±4.60% of control, p<0.01). The greatest inhibition (15.27 ±3.80% of control, p<0.0001) of cell 
survival was seen at 10 µg/mL RE (Figure 12A and 12B). Based on our data we calculated the 
RE concentration for the half maximal inhibition (IC50) of cell survival was 2.43 µg/mL. 
Exposure of the cells to 0.5 mM of paclitaxel resulted in a significant inhibition of cell survival 
(64.12 ±6.94% of control, p<0.05). Similarly, cell survival in PC-3 cells treated with 5 nM of 
PTX was also significantly inhibited (23.81 ±11.92% of control, p<0.0001) (Figure 12B). In 
addition, treatment with both 0.5 nM (59.18 ±9.45% of control p<0.01) and 5 nM docetaxel 
(8.50 ±8.50% of control p<0.0001) resulted in a significant inhibition of cell survival. It should 
be noted that the inhibition of PC-3 cell survival seen with 10 µg/mL of RE (15.27 ±3.80% of 
control, p<0.0001) was similar to the inhibition seen with 5 nM docetaxel (8.50 ±8.50% of 
control p<0.0001) in PC-3 prostate cancer cells.  
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Figure 12. Effect of rosemary extract on PC-3 prostate cancer cell survival. PC-3 cells were 
seeded (1000 cells/well) in a 6-well plate and exposed to the indicated concentrations of rosemary 
extract (RE) (A, B), paclitaxel (PTX) (B), or docetaxel (DTX) (B) for 7 days followed by fixing 
and staining with 0.05% methylene blue. Colonies of more than 50 cells were counted. Data are 
the mean ± SEM of 6 independent experiments. *p<0.05, **p<0.01, ****p<0.0001. 
 
 
0
0.
5 1
2.
5 5 10
0
25
50
75
100
RE Concentration (µg/mL)
C
e
ll
 S
u
rv
iv
a
l 
(%
 C
o
n
tr
o
l)
**** ****
****
****
**
C
on
tr
ol
R
E
 1
0 
µg
/m
L 
P
TX
 0
.5
 n
M
P
TX
 5
 n
M
D
TX
 0
.5
 n
M
D
TX
 5
 n
M
0
25
50
75
100
C
e
ll
 S
u
rv
iv
a
l 
(%
 C
o
n
tr
o
l)
**
****
*
****
****
Investigation of the Anti-Cancer Effects of Rosemary Extract in Human Breast and Prostate Cancer Cells 
 
 62 
4.2.3 Effects of RE on Akt signaling in PC-3 prostate cancer cells  
We also examined the effects of RE treatment on the activation of the Akt and measured 
the levels of Akt phosphorylation on the serine 473 residue, an established indicator of Akt 
activity [131]. Treatment of PC-3 breast cancer cells with rosemary extract (50 µg/mL) for 24 
hours did not result in a significant inhibition of Akt phosphorylation/activation (103.47 ±6.87% 
of control, p>0.05). However, PC-3 cells treated with RE for 48 hours (46.46 ±2.62% of control, 
p<0.01) resulted in a significant decrease in Akt phosphorylation/activation (Figure 13A and 
13B). The total Akt levels were also significantly inhibited by RE treatment for 48 hours (70.37 
±6.56% of control, p<0.01). Treatment of PC-3 cells with docetaxel for both 24 (100.75 
±12.91% of control, p>0.05) and 48 hours (89.42 ±18.17% of control, p>0.05) did not show a 
statistically significant inhibition of Akt phosphorylation/activation (Figure 13B).  
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Figure 13. Effect of rosemary extract on Akt signaling in PC-3 prostate cancer cells. Cell 
lysates were prepared from PC-3 prostate cancer cells treated without (control) or with 50 µg/mL 
rosemary extract (RE) for 24 or 48 hours. Cell lysates (20 µg) were immunoblotted using specific 
antibodies against Akt, phosphorylated/activated Akt, or -actin. A representative immunoblot is 
shown (A). The densitometry of the bands were corrected to -actin levels and expressed in 
arbitrary densitometry units as % of control. The data are the mean ± SEM of 3 independent 
experiments. **p<0.01.  
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4.2.4 Effects of RE on mTOR signaling in PC-3 prostate cancer cells  
Next, we examined  the effect of RE on mTOR phosphorylation/activation levels. 
Treatment of PC-3 cells with RE for both 24 (52.92 ±10.24% of control, p<0.01) and 48 hours 
(45.57 ±9.38% of control, p<0.001) resulted in a significant decrease in mTOR phosphorylation 
(Figure 14A and 14B). Treatment with RE also resulted in a statistically significant inhibition of 
total mTOR levels for both 24 (74.44 ±10.86% of control, p<0.01) and 48 hours (66.77 ±9.25% 
of control, p<0.001). Exposing PC-3 cells to docetaxel did not result in a statistically significant 
inhibition of mTOR phosphorylation/activation at either 24 (94.59 ±14.70% of control, p>0.05) 
or 48 hour (91.22 ±13.90% of control, p>0.05) treatment time (Figure 14B).  
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Figure 14. Effect of rosemary extract on mTOR signaling in PC-3 prostate cancer cells. Cell 
lysates were prepared from PC-3 cells treated without (control) or with 50 µg/mL rosemary 
extract (RE) for 24 and 48 hours. Cell lysates (20 µg) were immunoblotted using specific 
antibodies against mTOR, phosphorylated/activated mTOR or -actin. A representative 
immunoblot is shown (A). The densitometry of the bands were corrected to -actin levels and 
expressed in arbitrary densitometry units as % of control (B). The data are the mean ± SEM of 3 
independent experiments. **p<0.01, ***p<0.001. 
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4.2.5 Effects of RE on apoptosis in PC-3 prostate cancer cells  
The effect of RE on cell apoptosis was examined by measuring the levels of cleaved PARP, 
since it is an established indicator of apoptosis [80]. Exposing PC-3 prostate cancer cells to 
rosemary extract (50 µg/mL) for 24 hours resulted in a significant increase in the cleaved 
PARP/PARP ratio (177.9 ±14.50% of control, p<0.01) relative to the control indicating enhanced 
apoptosis (Figure 15A and 15B). Treatment of MDA-MB-231 cells with RE for 48 hours did not 
result in an increased cleaved PARP/PARP ratio (124.8 ±9.39% of control, p>0.05). 
Additionally, neither 24 (108.7 ±20.48% of control, p>0.05) or 48 hour (113.2 ±20.07% of 
control, p>0.05) docetaxel treatment enhanced the cleaved PARP/PARP ratio (Figure 15B).  
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(A) 
 
 (B) 
 
Figure 15. Effect of rosemary extract on PC-3 prostate cancer cell apoptosis. Cell lysates 
were prepared from PC-3 prostate cancer cells treated without (control) or with 50 µg/mL RE for 
24 or 48 hours. Cell lysates (20 µg) were immunoblotted using specific antibodies against PARP 
or -actin. A representative immunoblot is shown (A). The densitometry of the bands were 
corrected to -actin levels and expressed as a fold increase of arbitrary densitometry units as % 
of control (B). The data are the mean ± SEM of 3 independent experiments. *p<0.05. 
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 Figure 16 shows a representative image of control untreated, RE treated, and DTX treated 
PC-3 cells. No changes in cell morphology were observed with any of the treatments. It is 
important to note that the same number of cells were seeded in all wells. As it can be seen from 
Figure 16, treatment with 50 µg/mL of RE for 24 or 48 hours resulted in a substantial reduction 
of cell density relative to the control untreated groups. Although treatment with DTX for 24 and 
48 hours showed a reduction in cell density, it was not as great as the inhbition seen with RE. 
 
Figure 16.  Effect of rosemary extract and docetaxel on PC-3 cell morphology. Cells were 
treated without (control) or with RE (50 µg/mL) or DTX (10 nM) for 24 or 48 hours. Photographs 
were taken immediately after treatment (0 hr) and after the inidctaed time points using an EVOS 
XL Core Cell Imaging System by Life Technologies (10X magnification). 
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4.2.6 Effects of RE on PC-3 prostate cancer cell migration 
The wound healing assay was used to assess the ability of cancer cells to migrate. PC-3 
cells were exposed to 1 µg/mL of mitomycin-C (MMC) for 1 hour to inhibit cell proliferation 
and were then treated without (control) or with either 50 µg/mL rosemary extract or 10 nM 
docetaxel for 40 hours, just before complete wound closure. Treatment with rosemary extract 
was shown to significantly inhibit wound closure (56.14 ±3.48% of control, p<0.0001) indicating 
properties against cell migration (Figure 10B). A significant inhibition of cell migration was also 
seen when treating the cells with 10 nM docetaxel (70.92 ±2.35% of control, p<0.001), however 
this inhibition was not as great as the response seen with RE (Figure 17A and 17B). 
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(A) 
(B)  
 
Figure 17. Effect of rosemary extract on PC-3 prostate cancer cell migration. PC-3 cells were 
exposed to 1 µg/mL of mitomycin-C for one hour, followed by treated without or with 50 µg/mL 
rosemary extract (RE) or 10 nM docetaxel (DTX) for 40 hrs. Representative images of wound 
healing are shown immediately after being scratched with a 200 µL pipette tip (0 hr) and after 40 
hours of treatment (A). Wound closure was calculated as indicated in the methods and expressed 
as a percent of control untreated cells (B). The data are the mean ± SEM of 3 independent 
experiments. ***p<0.001, ****p<0.0001. 
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Table 7: Summary of the effects of RE on Akt and mTOR signaling by cell line. 
Cancer 
Cell Line 
Known Mutation 
Status 
Total Protein 
Level 
Phosphorylated 
Protein Level 
 
MDA-MB-231 
p53 null 
KRAS mutation 
 
Akt  
mTOR 
Akt  
mTOR  
 
PC-3 
p53 null 
PTEN null 
Akt   
mTOR  
Akt  
mTOR  
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Chapter 5: Discussion  
5.1 RE inhibits MDA-MB-231 breast cancer cell proliferation and survival   
In the present study we found a dose-dependent inhibition of MDA-MB-231 breast 
cancer cell proliferation with rosemary extract treatment. The highest inhibition of proliferation 
was seen at 50 µg/mL RE (34.79 ±2.321 % of control, p<0.0001) with a calculated IC50 value of 
28.86 µg/mL. Our data are in agreement with a few other studies [102,103,107,136] that have 
examined the effect of RE in breast cancer cells. In MCF-7 (ER+) and MDA-MB-231 breast 
cancer cells rosemary extract decreased cell viability in a dose-dependent manner, with an IC50 
value of 20.42 µg /mL [102]. Similarly, rosemary extract dose-dependently decreased viability of 
five breast cancer cell lines including MDA-MB-231 cells [103]. This suggests that only the 
effect of RE on cell viability has been previously investigated in MDA-MB-231 cells, thus 
making our findings novel. Apart from the above mentioned two studies [102,103] that examined 
the effect of RE on breast cancer cell viability, Marrelli et al. found that MCF-7 (ER+) breast 
cancer cells treated with 100 µg/mL of RE had reduced (45% of control) proliferation [107]. A 
study by Telang et al. found that treating HER-2 enriched 184-B5 mammary epithelial cells with 
10 µg/mL of RE inhibited cell cycle progression, inhibited the G1 to S phase transition and 
induced G1 phase arrest [136]. Collectively, these results suggest that RE may inhibit various 
breast cancer cells regardless of receptor status. Furthermore, the RE polyphenols carnosol, 
carnosic acid, and ursolic acid, effectively inhibited proliferation of ER positive MCF-7 breast 
cancer cells [136]. We have previously found an inhibition of A549 lung cancer cell proliferation 
by RE treatment [124] with an IC50 value of 15.9 µg/mL. Based on this evidence and comparing 
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the IC50 values it appears that TN breast cancer cells (IC50 28.86 µg/mL) are less sensitive to RE 
treatment than lung adenocarcinoma A549 cells (IC50 15.9 µg/mL) [124]. 
Apart from the suppression of cell proliferation, the present study found that treatment 
with RE inhibited clonogenic survival of MDA-MB-231 cells in a dose-dependent manner. 
Significant inhibition was seen at the lowest dose of 2.5 µg/mL RE (66.47 ±7.39% of control, 
p<0.001) and the highest inhibition was seen at 25 µg/mL RE (9.33 ±3.09% of control, 
p<0.0001) with a calculated IC50 value of 4.82 µg/mL. While no other studies have examined the 
effect of RE treatment on TN breast cancer cell survival, two studies using MCF-7 (ER+) breast 
cancer cells [103] and 184-B5/HER cells, which represent a model for the HER-2 enriched 
breast cancer subtype [136], found dose-dependent inhibition of survival with RE treatment. A 
calculated IC50 value of 4.6 µg/mL was found in RE treated 184-B5/HER cells. Comparing this 
IC50 of RE (4.6 µg/mL) to the one found in the present study (4.82 µg/mL) we see almost 
identical values suggesting that different breast cancer cells may have a similar sensitivity to RE. 
It is important to note that the inhibition of MDA-MB-231 cell proliferation and survival by RE 
treatment in the present study was greater than the inhibition seen with metformin or paclitaxel 
treatment. Metformin is derived from the plant Galega officinalis, commonly known as French 
lilac, used for many years in the management of type 2 diabetes mellitus [129] and many recent 
studies [127,128,137] have provided evidence of its anticancer properties. In previous studies by 
our lab, we found a significant inhibition of lung cancer cell proliferation and survival by 
metformin treatment [126] and for this reason we used it in the current study with the intention to 
serve as a positive control. Metformin (5mM) treatment did not have a significant effect on cell 
proliferation while it resulted in a significant inhibition of cell survival (63.36 ±6.01% of control) 
that was less than the inhibition seen with RE treatment. We also wished to compare the effect of 
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RE treatment with that of an agent used clinically to treat TN breast cancer and we used 
paclitaxel. Specific chemotherapeutic agents targeting TN breast cancer do not exist and this type 
of cancer is often treated using paclitaxel [36,130,138]. Cell viability and proliferation of TN 
breast cancer cells was decreased with paclitaxel treatment in previous studies [103,130]. TN 
breast cancer patients treated with paclitaxel have serum levels of paclitaxel in the nanomolar (12 
nM) [138] to the micromolar (3.3 µM) [139] range. In the present study we found a significant 
inhibition of proliferation, and survival with 2-10 nM paclitaxel treatment. We used these 
concentrations of paclitaxel based on previous in vitro studies [103,130] and taking into account 
the paclitaxel serum levels in treated patients [138,139]. Importantly, the effects of RE treatment 
were greater than the effect of paclitaxel and these data suggest a strong anticancer potential of 
RE that justifies further studies 
 
5.2 Exploring the effect of RE on signaling molecules involved in breast cancer  
 The effect of RE on signaling pathways that control MDA-MB-231 cell proliferation and 
survival has not been studied previously. It should be noted that the levels of phosphorylated Akt 
(Figure 6) in the control untreated MDA-MB-231 cells are high compared to normal cells, 
indicating that this may be driving proliferation and survival. Akt controls cellular growth and 
survival/apoptosis [140] and its activation is increased in breast cancer cells including breast 
cancer [3,56,140,141]. Our observation is in agreement with other studies that have shown that 
the levels of phosphorylated/activated Akt  are high in TN breast cancer [142]. Importantly, our 
study is the first to show that treatment with 50 µg/mL RE significantly inhibited 
phosphorylation/activation of Akt (Figure 6). The recognition of enhanced Akt signaling in 
cancer, including breast cancer [143,144], has led to the development of novel agents targeting 
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Akt, such as perifosine, SF1126, PX166, BEZ256, and EX147, all currently in clinical trials 
[143]. RE has a potent inhibitory effect on Akt, comparable to the above mentioned Akt 
inhibitors, and deserves attention and further investigation. 
In addition to Akt, mTOR, a signaling molecule that promotes protein synthesis, cell 
proliferation and survival, is often activated in cancer due to mutations that are found upstream 
of mTOR itself, such as a gain-of-function mutation of PI3K and loss-of-function mutations on 
the tumor suppressor gene PTEN [13]. The activation of mTOR increases the rate of protein 
synthesis and suppresses autophagy in cancer cells [145]. It has been shown that activated 
mTOR leads to increased tumor progression and decreased patient survival, importantly, mTOR 
activation has been reported to be common in TN breast cancer [145,146]. In agreement with 
these evidence, we observed that the phosphorylation/activation levels of mTOR in the control 
untreated MDA-MB-231 cells (Figure 7) were high indicating its overactivation. Our data show 
a very potent inhibition of mTOR with RE treatment and are clinically relevant since 
development of effective mTOR inhibitors are highly desired to be used in the treatment of 
cancer. Rapamycin (sirolimus), the first discovered mTOR inhibitor, has been shown to inhibit 
cell growth in several types of cancer including breast [75,145]. However, rapamycin is not 
widely used as a cancer monotherapy due to its poor pharmacokinetics and low solubility [145].  
We observed potent inhibition of both Akt and mTOR phosphorylation/activation with 
RE treatment in the present study. As mentioned above, effective inhibitors of Akt, mTOR or 
both are highly desired and employed in the treatment of TN breast cancer [64,147]. An early 
phase clinical trial showed that ipatasertib, an Akt inhibitor, combined with paclitaxel improved 
the progression-free survival of patients with TN breast cancer compared to paclitaxel alone (6.2 
vs. 4.9 months, p=0.037) [148]. Another phase II study showed that the combination of 
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ipatasertib (400 mg daily) and paclitaxel (80 mg/m2 weekly) was well tolerated by women with 
TN breast cancer [63]. The mTOR inhibitor everolimus was shown to increase the effectiveness 
of paclitaxel in treating patients with TN breast cancer in clinical trials [64]. 
It is important to note that apart of the reduction in the phosphorylated/activated Akt and 
mTOR levels, seen with RE treatment in our study, our data showed a significant reduction in the 
total Akt and mTOR levels. The reduction in total Akt levels seen in our study is significant. 
Similar to our data, treatment with salinomycin, an antibiotic with selective activity against some 
cancer cells, alone or in combination with MK-2206, an allosteric Akt inhibitor, resulted in 
reduced phosphorylated and total Akt levels in Hs578T breast cancer cells [149]. Total mTOR 
protein levels are elevated in breast cancer compared to normal cells [150]. Although mTOR 
inhibitors have shown promise as anti-cancer agents, there is a high risk of drug resistance [150]. 
Inhibition of mTOR initiates a feedback loop that upregulates upstream receptor tyrosine 
kinases, which activate Akt, and reactivate mTOR limiting the effectiveness of these inhibitors 
[66,151]. This feedback regulation of mTOR involves increased levels of total-mTOR and is a 
suggested mechanism of drug resistance [150]. Thus, utilizing an agent that will inhibit the 
expression of the mTOR protein, in addition to the inhibition of mTOR activation, may 
potentially improve the efficacy of breast cancer treatments and decrease drug resistance [150]. 
Similar to our data, it was shown that MCF-7 breast cancer cells treated with metformin and 
rapamycin, two known mTOR inhibitors, decreased levels of both total and 
phosphorylated/activated mTOR [150]. Overall, utilizing agents that target Akt/mTOR and 
inhibit both phosphorylated and total levels of these proteins, may result in increased 
sensitization to treatments and reduced drug-resistance. 
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RE also enhanced the level of cleaved PARP (Figure 5), a well-established marker of 
apoptosis [80]. A previous study by our group also found a two-fold increase in PARP cleavage 
in A549 non-small cell lung cancer cells treated with RE [124]. Similar to our findings, treatment 
of MDA-MB-231 cells with carnosol, an RE polyphenol, resulted in increased apoptosis, as 
indicated by increased cleaved PARP levels and increased cleaved caspase 3, 8, and 9 levels 
[113]. Carnosol was also seen to increase the expression of the pro-apoptotic protein Bax and 
decrease the anti-apoptotic protein Bcl2 [113]. It is possible that the pro-apoptotic effect seen 
with the RE treatment in our study may be due to carnosol or other polyphenols found in RE. 
Previously, we have measured the levels of the polyphenols carnosic acid and rosmarinic acid in 
our extract and found it to be 2.12 ±0.22% [152] and 13.39 ±0.23% [153], respectively. A few in 
vitro studies have shown that carnosic acid, rosmarinic acid, and carnosol inhibited cell 
proliferation and induced apoptosis in various breast cancer cell lines [102,106,113,154]. 
Specifically, carnosic acid was shown to inhibit proliferation in ER-negative human breast 
cancer cells by inducing G1 cell cycle arrest [106]. Treatment with carnosic acid (19 µM) 
showed 70% inhibition of MCF-7 (ER+) breast cancer cell viability, while a 2-fold greater 
inhibition was seen in the estrogen independent TN MDA-MB-231 breast cancer cells [102]. 
Similarly, carnosol reduced the cell viability of MDA-MB-231 breast cancer cells in a dose-
dependent manner with an IC50 value of 83 µM [113]. Interestingly, rosmarinic acid did not 
inhibit proliferation of MDA-MB-231 breast cancer cells [102] suggesting that this polyphenol 
may not be responsible for the anti-proliferative effects shown by RE treatment. Based on these 
studies we hypothesize that the polyphenols carnosic acid and carnosol may be responsible for 
the observed effects of RE in the present study. 
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There are no studies examining the effects of RE treatment using TN breast cancer 
xenograft models. In one study, intraperitoneal injections of RE or carnosol at 200 mg/kg for 5 
days in female rats inhibited the DMBA-induced mammary adduct formation (44% and 40% 
respectively) [115]. In another study, administration of carnosic acid to mice inoculated with ER 
positive breast cancer cells resulted in significant inhibition of tumor growth [109]. Furthermore, 
treatment of mice xenografted with ER positive breast cancer cells with carnosic acid and 
tamoxifen (30 and 10 mg/kg, respectively) as a combined therapy resulted in a greater inhibition 
of tumor growth in comparison to carnosic acid or tamoxifen monotherapy [109]. Although the 
studies examining the effects of rosemary extract and rosemary extract polyphenols in vivo are 
limited, the available evidence suggest that they may be effective in inhibiting tumor growth as a 
monotherapy or as a combined therapy with other chemotherapeutic agents. In vivo animal 
studies utilizing TN breast cancer xenograft models are required to better understand the effects 
of RE and RE polyphenols against this subtype of cancer.  
 
5.3 RE inhibits PC-3 prostate cancer cell proliferation and survival   
The present study found a dose-dependent inhibition of PC-3 prostate cancer cell 
proliferation with rosemary extract treatment. The highest inhibition was seen at 50 µg/mL 
(26.51 ±2.95% of control, p<0.0001) RE with an IC50 19.72 µg/mL. A significant inhibition of 
cell proliferation was first measured at 10 µg/mL of rosemary extract (80.25 ±4.44% of control, 
p<0.01). Our data are in agreement with other studies [102,117] that have examined the effect of 
RE in prostate cancer cells. Similar to our findings treatment with RE decreased proliferation of 
22RV1 (76.5%) and LNCaP (94.6%) prostate cancer cells [117]. Cell viability was also 
decreased in a dose-dependent manner, the observed IC50 values for 22RV1 and LNCaP cells 
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was 13.3 µg/mL and 27 µg/mL, respectively [117]. Another study showed that RE dose-
dependently decreased cell proliferation in various human cancer cell lines including DU145 
(human prostate carcinoma) cells [102]. Furthermore, the RE polyphenol carnosic acid was 
shown to significantly decrease cell proliferation in PC-3, LNCaP, DU145, and 22RV1 prostate 
cancer cells in various studies [118–120]. When comparing the calculated IC50 values it appears 
that PC-3 cells (19.72 µg/mL) are more sensitive to RE treatment than breast adenocarcinoma 
MDA-MB-231 cells (28.86 µg/mL) shown in this study, but less sensitive than lung 
adenocarcinoma A549 cells (IC50 15.9 µg/mL) [124].  
Apart from cell proliferation, the effects of RE on cell survival were also examined in 
PC-3 cells. A highest inhibition of cell survival was seen with 10 µg/mL RE treatment (15.27 
±3.80% of control, p<0.0001), with a calculated IC50 value of 2.43 µg/mL. A significant 
inhibition of cell survival was seen even when using RE concentrations as low as 0.5 (80.20 
±4.60% of control, p<0.01) and 1 µg/mL (57.73 ±6.19% of control, p<0.0001). It is important to 
note that the inhibition of PC-3 cell survival seen with 10 µg/mL RE (15.27 ±3.80% of control, 
p<0.0001) was similar to the inhibition seen with 5 nM DTX (8.50 ±8.50% of control, p<0.0001) 
treatment and greater than the inhibition seen with 5 nM PTX (23.81 ±11.92% of control, 
p<0.0001). Another study found that the rosemary polyphenol rosmarinic acid (200 µM), 
inhibited PC-3 and DU145 prostate cancer cell survival [155]. This suggests that RA may play a 
role in the inhibition of PC-3 cell survival seen with rosemary extract. Based on the IC50 values 
determined using the findings from our study examining the inhibitory effect of RE on cell 
survival, PC-3 cells (2.43 µg/mL) appear to be more sensitive to rosemary extract treatment than 
MDA-MB-231 cells (4.82 µg/mL).  
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5.4 Exploring the effect of RE on signaling molecules involved in prostate cancer 
 The effects of RE on Akt and mTOR signaling were examined in PC-3 prostate cancer 
cells. Our study showed a significant inhibition of Akt phosphorylation/activation (46.46 ±2.62% 
of control, p<0.01) with 50 µg/mL RE treatment for 48 hours (Figure 13). Total Akt values were 
also significantly reduced during 48 hour treatment (70.37 ±6.56% of control, p<0.01), similar to 
our findings in MDA-MB-231 cells. Cells treated with RE for 24 hours did not result in any 
inhibition of phosphorylated/activated Akt (103.47 ±6.87% of control, p>0.05). Phosphorylated 
levels of Akt were also not significantly decreased by either 24 hour (100.75 ±12.91% of control, 
p>0.05) or 48 hour (89.42 ±18.17% of control, p>0.05) DTX treatment. There are no other 
studies examining the effects of RE on Akt signaling in PC-3 prostate cancer cells, thus making 
our findings novel. However, a previous study by our group treated A549 non-small cell lung 
cancer (NSCLC) cells with 50 µg/mL RE and also found a significant inhibition of Akt 
phosphorylation/activation (36.1 ±4.9% of control, p<0.001) [124]. mTOR is a downstream 
target of Akt and therefore, the effects of RE were also examined on this signaling molecule. 
Treatment with RE for 24 hours decreased mTOR phosphorylation/activation in PC-3 cells 
(52.92 ±10.24% of control, p<0.01). Interestingly, total mTOR levels were also decreased with 
24 hour RE treatment (74.44 ±10.86% of control, p<0.01). A significant inhibition of mTOR 
phosphorylation/activation (45.57 ±9.38% of control, p<0.001) was also seen with 48 hour RE 
treatment (Figure 14). In accordance with our findings in MDA-MB-231 cells, PC-3 cells treated 
with RE for 48 hours had decreased total mTOR levels (66.77 ±9.25% of control, p<0.001). 
Also, 24 hour RE treatment increased the cleaved PARP/PARP ratio in PC-3 cells (177.9 
±14.50% of control, p<0.01), while 48 hour treatment showed a tendency to enhance cleaved 
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PARP but was not significant (124.8 ±9.39% of control, p>0.05) (Figure 15). Our study did not 
examine the effect of rosemary extract on p70S6K, a downstream target of mTOR, in either 
MDA-MB-231 or PC-3 cells. However, it was previously shown by our group that RE 
significantly inhibited both activated (57.2 ±14.8% of control, p<0.05) and total (83.3 ±2.5% of 
control, p<0.05) p70S6K levels in A549 NSCLC cells [124]. Therefore, RE may also inhibit 
p70S6K in MDA-MB-231 breast and PC-3 prostate cancer cells, however future studies must be 
performed in order to confirm this.   
The PI3K/Akt signaling pathway is commonly aberrant in metastatic prostate cancer 
[156]. Multiple Akt inhibitors are currently in various stages of clinical development [63,157]. 
These inhibitors fall into two main classes: ATP-competitive inhibitors and allosteric inhibitors 
of Akt [63,157,158]. Additionally, the loss of the tumor suppressor gene PTEN, as seen in PC-3 
cells is associated with a poor prognosis in patients [156]. A phase II clinical study examined the 
effects of ipatasertib, an Akt inhibitor, combined with the anti-androgen medication abiraterone 
acetate, in patients with metastatic castration-resistant prostate cancer [159]. The combined 
treatment of ipatasertib and abiraterone acetate showed trends toward improved progression-free 
survival [159]. Importantly, in patients with PTEN loss tumors, measures of anti-tumor activity 
were greater with ipatasertib and abiraterone acetate combined treatment. This suggests that 
PTEN loss tumors may benefit greatly from Akt and AR inhibition.  
In addition, it was found that the dual PI3K/Akt and mTOR inhibitor, NVP-BEZ235 (40 
mg/kg), when used as a combined therapy with paclitaxel (4 mg/kg) resulted in a greater 
inhibition of tumor growth in castrated mice xenografted with C4-2AT6 prostate cancer cells 
than monotherapy treatments [160]. It is also suggested that the inhibition of  PI3K/Akt/mTOR 
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signaling by NVP-BEZ235 can overcome docetaxel resistance in human castration resistant 
prostate cancer [160]. A study by Millis et al. analyzed solid tumor samples in 19,784 patients 
with over 40 types of cancer and identified aberrations in the PI3K/Akt/mTOR pathway in 38% 
of samples, indictaing an urgent need to find chemicals that can target signaling molecules 
involved in this pathway [161]. In our study RE has shown anti-proliferative activity, and an 
inhibition of Akt and mTOR in both MDA-MB-231 breast cancer and PC-3 prostate cancer cells, 
suggesting that with further research RE may have potential as a chemotherapeutic agent. 
 The inhibition of total Akt and mTOR levels with RE treatment (Figures 13 and 14) 
suggests that this reduction could be due to the inhibition of gene transcription, inhibition of 
protein synthesis, or increased protein degradation. RE may also have an effect on protein 
stability. The inhibition of total Akt protein and mRNA levels has previously been reported in 
K562 leukemia cells treated with 50 µg/mL for 24 to 48 hours [162]. The same study also found 
that terpinolene, a constituent of rosemary and sage, but not COH, RA, or linalool, among some 
of the main components of rosemary tested, reduced Akt protein expression in K526 cells [162]. 
Additionally, a previous study by our group showed an significant reduction of both total Akt 
and mTOR expression by 50 µg/mL RE treatment in A549 lung cancer cells [124]. It is 
important to note that the inhibitory effects of rosemary extract on Akt and mTOR observed in 
the present study are similar to the effects of perifosine, a novel inhibitor of Akt, currently in 
clinical trials. Perifosine inhibited Akt phosphorylation and reduced total Akt levels in H157, 
H460, and A549 NSCLC cells [163]. Similarly, in HCT116 human colon cancer cells perifosine 
inhibited Akt phosphorylation and reduced total Akt, mTOR, and p70S6K levels resulting in the 
induction of apoptosis and autophagy [164].    
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5.5 RE inhibits MDA-MB-231 breast and PC-3 prostate cancer cell migration 
  Treatment with rosemary extract (50 µg/mL) showed a significant inhibition of MDA-
MB-231 cell migration (65.15 ±0.97% of control, p<0.001) that was comparable to the response 
seen with 10 nM paclitaxel (78.44 ±5.60% of control, p<0.01) (Figure 10). Similarly, RE treated 
PC-3 cells also showed a significant inhibition of cell migration (56.14 ±3.48% of control, 
p<0.0001) that was comparable to response seen with docetaxel (70.92 ±2.35% of control, 
p<0.001) (Figure 17). The inhibitory effects of RE on cell migration have been tested in HGUE-
C-1, HT-29, and SW480 human colon cells [165]. Treatment with 30 and 40 µg/mL RE 
significantly inhibited cell migration in all the aforementioned cell lines [165]. Although no other 
studies exist examining the anti-migratory or anti-metastatic effects of RE in TN breast or 
prostate cancer cells, one study found a significant inhibition of MDA-MB-231 cell migration 
when treated with the rosemary polyphenol carnosic acid [154]. In addition, the inhibition of cell 
migration seen with carnosic acid in combination with trastuzumab, a chemotherapeutic agent 
used in clinical practice, resulted in a greater inhibition of cell migration when compared to each 
agent alone as a monotherapy [154]. These data indicate a chemo-sensitive effect of RE 
polyphenols. 
 
5.6 Limitations and future directions  
 One limitation of this study is that it was performed in vitro using a cell culture model 
and has limited applicability and generalizability physiologically, towards human models of 
cancer. However, cell culture is a well-established model for exploring the anti-cancer effects of 
novel compounds to determine their potential use in vivo and to establish concentrations that are 
effective at the cellular level. The major advantage of using cell culture is the consistency and 
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reproducibility of results and that the cellular environment can be easily manipulated to examine 
different conditions. Importantly, in vitro studies using human cancer cells provide the 
opportunity to examine cell signaling questions, perform experiments by over-expressing or 
eliminating the expression of a specific protein and find potential drug targets. Following studies 
in vitro, in vivo xenograft studies must be performed and if the data are promising, clinical 
human studies should follow. When the mechanism of the anti-cancer effects of RE have been 
well established in vitro, studies using in vivo xenograft models of breast and prostate cancer in 
mice should be performed. These studies can further examine effective doses and the 
bioavailability of RE to support its use in human clinical trials. 
Another limitation of the present study is the lack of studies using healthy, non-cancerous 
breast and prostate cancer cells. Future studies should examine the effects of RE in normal breast 
and prostate epithelial cells to see if our extract can specifically target cancer cells while sparing 
normal healthy cells. Cell lines with no known mutations such as the mammary epithelial cell 
line 184B5 and the prostate epithelial cell line PNT1A should be used to compare the effects of 
RE in cancer cells to non-cancerous cells.  
In the present study only one cell line representing TN breast cancer and prostate cancer 
was used and this presents another limitation. In the future, other cancer cell lines representing 
various subtypes of breast cancer such as those that express hormone receptors (MCF-7), HER-2 
(BT474), and other TN breast cancer cell lines (MDA-MB-436) should also be examined. 
Additionally, various prostate cancer cell lines that are androgen receptor responsive (LNCaP) 
and other androgen receptor negative (DU145) cell lines should also be used to further support 
the anti-cancer effects of RE in vitro.  
Importantly, it is unclear whether RE treatment is causing cell death (cytotoxic effects) or 
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inhibiting cell growth/proliferation (cytostatic effects) in MDA-MB-231breast and PC-3 prostate 
cancer cells. Future studies should use a second validation of apoptosis; such as trypan blue dye 
or propidium iodide staining in order to determine what the exact effect of rosemary extract is in 
cancer cells.  
 In this study, we chose to examine the effects of RE on the Akt and mTOR signaling 
molecules because these are often mutated in cancer and thus lead to increased cell proliferation 
and an inhibition of apoptosis. Cancer signaling is very complex and therefore, it would be 
beneficial to look at other signaling molecules involved in regulating cell proliferation and 
survival. Future studies should explore other signaling molecules involved in regulating 
proliferation and survival/apoptosis by Western blotting. Since the effects of RE on the signaling 
molecules involved in cell proliferation and survival varied between the two cell lines it would 
be interesting to use inhibitors to knockdown the expression of Akt and examine how this alters 
the effects seen by RE treatment.  
Combination therapies are useful in treating cancer because they can target different 
signaling pathways at once and decrease chemo-resistance. Future studies should investigate the 
effect of RE in combination with current chemotherapeutic agents such as paclitaxel, docetaxel, 
or other natural compounds that have shown anti-cancer activity such as resveratrol.  
A plant extract was used in the present study which may contain numerous bioactive 
compounds accounting for the observed effects. Finding these bioactive compounds should be 
the focus of future studies. Certain polyphenols, such as carnosic acid, carnosol and rosmarinic 
acid, contained within rosemary extract may play a role. Pilot studies in our lab indicate that 
carnosol and carnosic acid but not rosmarinic acid have anti-proliferative (Figure s3) and anti-
survival effects.  
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5.7 Summary/Conclusions 
 
Figure 18. Effects of rosemary extract on MDA-MB-231 triple negative breast cancer and 
PC-3 prostate cancer cell signaling molecules. RE inhibited the phosphorylation/activation and 
total levels of Akt and mTOR, while enhancing the levels of cleaved PARP. 
 
Breast cancer is the most frequently diagnosed and the second leading cause of cancer-
related death among women in North America. Similarly, prostate cancer is the most commonly 
diagnosed type of cancer and second leading cause of cancer-related death among men in North 
America. Thus, both breast and prostate cancer cell lines were used in this study to represent the 
most common types of cancer found in patients. Triple negative breast cancer is one of the most 
aggressive subtypes of breast cancer and does not respond to conventional hormone therapy. 
Prostate cancers that are not responsive to hormone therapy display increased metastatic 
potential and are highly aggressive, therefore innovative treatments are being sought for both of 
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these types of cancer. Rosemary extract has a high polyphenolic content and has been previously 
shown to have antioxidant, anti-inflammatory, anti-microbial, anti-diabetic, and anti-cancer 
effects. This study aimed to examine the anti-cancer effects of RE in TN breast cancer cells and 
androgen receptor negative prostate cancer cells, as well as the potential underlying signaling 
mechanisms involved.  
The present study is one of the few studies that has examined the effects of rosemary extract 
on MDA-MB-231 triple negative breast cancer and PC-3 prostate cancer cells. We found that RE 
significantly inhibited MDA-MB-231 and PC-3 cell proliferation, and survival at significantly 
low concentrations (0.5-20 µg/mL). The levels of cleaved PARP, an established marker of 
cellular apoptosis, were increased by RE treatment for 24 and 48 hours in MDA-MB-231 cells 
however, cleaved PARP was only increased with 24 hour RE treatment in PC-3 cells, suggesting 
that the growth inhibitory effect may vary by cell line. Importantly, RE significantly reduced the 
phosphorylation/activation levels of Akt and mTOR, key players controlling cancer cell 
proliferation and survival. These effects were comparable to the effects of paclitaxel and 
docetaxel, chemotherapeutic agents that are currently used in the treatment of TN breast cancer 
and prostate cancer.  
Our data indicate that RE may have a role as a potential chemopreventive or 
chemotherapeutic agent and could act as a dual Akt and mTOR inhibitor. Further research should 
investigate a) the exact polyphenolic constituent(s) of rosemary extract that contribute to its anti-
cancer effects, b) prostate and mammary epithelial cell lines representing healthy/non-cancerous 
cells should be used for comparison and c) the effects of RE and RE polyphenols should be 
explored further using in vivo animal models xenografted with triple negative breast cancer cells 
and androgen receptor negative prostate cancer cells. 
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Appendix 
Supplemental Figures: 
 
Figure s1. Effect of CA on MDA-MB-231 breast cancer cell proliferation. MDA-MB-231 
cells were treated without (control) or with the indicated concentrations of carnosic acid (CA) for 
72h followed by fixing and staining with 0.5% crystal violet. The stain was solubilized, and 
absorbance was read at 570 nm. Data are the mean ± SEM of 3 independent experiments. *p<0.05, 
**p<0.01,***p<0.001.  
 
 
Figure s2. Effect of RA on MDA-MB-231 breast cancer cell proliferation. MDA-MB-231 
cells were treated without (control) or with the indicated concentrations of rosmarinic acid (RA) 
for 72h followed by fixing and staining with 0.5% crystal violet. The stain was solubilized, and 
absorbance was read at 570 nm. Data are the mean ± SEM of 3 independent experiments.  
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Figure s3. Comparing the effects of CA and RA on MDA-MB-231 breast cancer cell 
proliferation. MDA-MB-231 cells were treated without (control) or with the indicated 
concentrations of either carnosic acid (CA) or rosmarinic acid (RA) for 72h followed by fixing 
and staining with 0.5% crystal violet. The stain was solubilized, and absorbance was read at 570 
nm. Data are the mean ± SEM of 3 independent experiments.  
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